How To Land A Literary Agent, According To Iris Blasi Of Carol Mann Agency (Part 2) – Forbes

Yesterday I shared part 1 of my interview with literary agent Iris Blasi of Carol Mann Agency about getting your nonfiction manuscript published. Today, Blasi discusses the specifics of selling memoir as a genre, author submission deal breakers, and how authors can best position themselves to get signed by an agent.

You mentioned memoir, where youre basically selling yourself. Is memoir different in terms of what it takes to sell one?

The ways memoirs are pitched to agents and publishers is different. Generally in the nonfiction world, books can be sold on proposal. Thats the summary, comp titles, marketing and publicity section, about the author, annotated table of contents and a couple sample chapters that show how you would do this if you had an advance and a book deal. The flip side is that on the fiction side, the vast majority of fiction is sold with a completed manuscript.

The only nonfiction that is usually sold in its completed form is memoir. The idea is that when you get an advance, you need time to report on the subject. Memoir is a lived experience that youve already had, so you wont need the advance to do that kind of heavy lifting or international global travel, whatever the case may be. And with memoir, you cant just promise I plan to look at X. Any acquiring editor would need to know the full arc of that story, just as they do in fiction.

There are lots of rhythms of memoir that mirror fiction writing. You hear people say my life is so crazy, people always say I should write a book. Memoir is tricky because you have to give people a reason to care about your story. It cant just be that its wild.

Hachette Books

You can see that successful memoirs tap into something thats happening, something thats topical or a universality of a lived experience. Stephanie Lands Maidfelt incredibly timely to me with a lot of the topics were confronting in the political realm. Its the same thing were asking for in all kinds of books. Its not just,This is a good book. Its, Why does it matter to us right now?

Readers have so much to choose from. Theyre not just choosing from a wide array of books. We have to get them to choose a book on top of cooking something for dinner or watching a movie or bingeing something on Netflix. Why are we going to publish something? We have to explain to the reader why its worth their investment of the 8-12 hours that it takes to read a book.

Do you have any other memoirs that are the kind of storytelling you would want to publish?

Buzz is actually a perfect example: Its a nonfiction journalistic approach to a topic that arises out of Hallies experiences. She talks about a formative experience seeing a sex toy for the first time, and she also delves into her tenue during grad school selling for a local in-home sex-toy sales business. You understand in the book why she cares so much about that subject matter.

Another favorite book I did in that vein was Peter Rudiak-Goulds Surviving Paradise: One Year on a Disappearing Island, which used Peters experience teaching English on a remote atoll in the Marshall Islands too talk about the threat global warming posed to the already precarious existence of these low-lying islands.

I love in particular books that are a hybrid of memoir and something else. Bill Hayes has done this kind of thing repeatedly by interweaving a personal narrative with a larger reported piece. His book Sleep Demons is a favorite of mine in which he co-mingles his own battle with insomnia with the scientific history of sleep research and clinical sleep disorders. He tackled the subject of blood in a similar way with Five Quarts which addresses the subject through the lens of living with his partners HIV status.

Alexandria Marzano-Lesnevichs The Fact of a Body maps the legal case of a pedophile murderer against the authors own history of sexual abuse and family secrets. Or I think, too, of Maggie Nelsons The Red Parts, which is nominally an account of the author attending the years-delayed murder trial of her aunt, but also delves into a meditation on memory, the fallibility of forensics, the grieving process, the justice system and moreits like Joan Didion meets Making a Murderer. Or one of my favorite books ever, Walter Kirns Blood Will Out, which is nominally a memoir about Kirns experience with the con artist who posed as Clark Rockefeller that is really an incredible rumination on identity and class. I think that the most exciting memoirs tend to do more than one thing.

What do you see in proposals thats a deal breaker?

Mass submission. Digital technology means you can send your manuscript to every agent who is alive and thats never a wonderful idea.

How does an author know an agent is the right fit?

Its somebody who understand what youre trying to do, who sees your vision, is passionate about the book. Nobody works in publishing for the money. You have to have that genuine enthusiasm. When you look at books that are successful, its because they all caught early, and that germ of excitement has to come at the beginning of the process. Its contagious. The author is excited about their work, they find an agent whos excited about it too, they make an editor excited, the editor gets their editorial board excited, and the publicity and marketing and sales teams all get excited.

People often ask how much I think a certain book can sell for. Publishing is very unpredictable and I never promise. People think a book is their get-rich idea. It can take a couple books to get to the level where they want to be. Not everybodys first book out of the gate will be that bestseller. Youre looking for somebody whos willing to put in that work with you.

All literary relationships are at the end of the day partnerships, but the editor/author relationship can feel more transactional because the publishing house is paying the author to write a book that they will then publish. The agent/writer relationship can feel a little bit more like being in the trenches together. You have to think about: who do you want down there with you?

What can authors do to best position themselves to be signed by an agent?

I want to work with authors who have not only lofty goals but an idea of the pathway to get there. They need to understand the building blocks. Im going to then meet them halfway by show up with all of the tools in my own arsenal so we can create this empire together. Agenting feels much more like being on a team with somebody because my financial future is very directly tied to theirs. I need to be working with people that I 185% believe in.

Thats what happened with Lindsay Goldwert. I reached out her in early 2018 because I admired her writing but I also just really respected her hustle. I wanted to know what book ideas she might have floating around in her head and how I could help make that happen.

Tiller Press

The ideas we originally talked about werent even the book we wound up selling: Bow Down: Lessons from Dominatrixes on How To Get Everything You Want, which will be published by Simon & Schuster imprint Tiller Press in January 2020. But when Lindsay said she wanted to write a book about what professional dominatrixes can teach the rest of us about confidence, power, and happiness, I was on board, and the book turned out so incredibly. Its a modern empowerment primer for women, but its also such an intimate and thoughtful look at Lindsays own evolving views on personal power and self-confidence. And its funny as hell. Theres no one else who could have written the book the way she did. Im so excited to see what Lindsay does next. I believe in her so much that I will back her on literally whatever she wants to do.

As an editor I would get letters from authors saying, Im looking for an agent. As an agent, I get people saying, Im looking for a publishing house. That automatically shows me theyre not paying attention to who I am and what I do. It starts with the little things. Use my name.

Im so public with the things I like in terms of my literary tastes. Take two seconds and look onTwitterorInstagram. Are we connecting with something there? Do you know any other books Ive ever published? Do you know other books that our agency has published? We have a 40-year track record with a authors including Paul Auster, Tim Egan, Erin Brockovich, Queen Latifah, DMC, Kitten Lady, Pusheen, and The Oatmeal. Its a huge range.

Is there any book weve ever published that you admire? Its helpful to know that, as not only does it mean that youre paying attention and that I should then pay the same amount of attention in response, but it gives me an idea of what youre looking to do so I can then have a clearer idea of what I can bring to the table to help you get there.

How much back and forth and revising of the proposal usually happens? What can they expect after you sign them as a client?

Because I come out of an editorial background, Im a very editorially-focused agent. I would say signing is just the beginning of the process. We would work together to make this be the best that it can be, whatever that back and forth involves. It may take months to get to the point where we feel right about submitting it.

It may not be just about the manuscript. It may be platform building. Because I also have experience in publicity and marketing (my last in-house position was a hybrid role where I was both Marketing Director and Senior Editor), that kind of coaching and consultation is something I offer that is somewhat unique to me as an agent.

We want to make sure the whole package looks the way its supposed to before we approach the publisher. Does that mean setting you up with a speakers bureau to book some speaking gigs? Does it mean that I help you write and place a high-profile op-ed before we submit the proposal to publishers? As an agent, I am on board for a clients whole career, so we can talk and strategize about some of that long-term planning as part of the preparation of a proposal.

What kind of timeline can they expect from signing with you to hearing back from publishers?

The submission timeline is as unique as every book. Id say generally it can be between one and six months, depending on what shape the proposal is in. You have to think about the timing of the rhythms of the publishing year and when the right time to go out with something is. Sometimes it does take a long time. My colleagues have worked with people for two to three years before they went out with a selling proposal. That can also happen. Its generally worth the time it takes for the book and whole pitch to become the best it can be. If youre looking for a get-rich-quick scheme, I would advise not writing a book.

Original post:

How To Land A Literary Agent, According To Iris Blasi Of Carol Mann Agency (Part 2) - Forbes

Stick to What Resonates Within You: Mother-Daughter Duo Sophie and Gaa Jacquet-Matisse on How to Thrive in a Changing Art World – artnet News

From One Woman to Another, a five-part series co-produced by artnet News and Mark Cross, features intimate, candid conversations between eminent women at the pinnacle of the art industry and a mentor or protg of their choosing, paired with original photography by David Lipman.

In the final installment of the series, artnet News contributor Maria Vogel interviewed artist Sophie Matisse and her daughter, the fashion designer Gaa Jacquet-Matisse.

Painter Sophie Matissethe granddaughter of the towering Modernist Henri Matisse and step-granddaughter of pioneering Dadaist Marcel Duchamphas a bond with her daughter, Gaa, that defies the typical mother-daughter relationship. Not only do they share the weight of great expectations, considering their lineage; they also have chosen careers that speak to their shared belief in staying true to themselves, which affords them a special kind of bond.

Though different in their demeanors and individual pursuits, they are self-described best friendsand, more than that, Sophie considers her daughter to be a mentor, and her closest confidante.

We spoke to the two about the special nature of their unwavering support of one another, how they have seen the art world change, and how they would advise young women entering the culture industry.

Tell me a bit about your backgrounds. How did you both fall in love with art? Do you remember the moment you connected with art significantly for the first time?

Sophie Matisse: Needless to say, I have a family thats submerged in the art realm. While I grew up with that, I was kind of sheltered from it too. My father wasnt a huge fan of making it a big deal. He had to grow up with ithe was closer to the fire, so to speak. So I kind of had a protected childhood, which I feel blessed to have had.

As a child, I had learning issues that I think can be attributed to a speck of dyslexia. Because of that, I realized anything that was expressed in an art form was much more fluid and natural for me. It was a language I stuck to because it was so convenient.

Gaa Jacquet-Matisse: With my mothers entire side of the family being artists, and my parents being painters, I was immersed in the art world from a very young age. I remember whenever we would go to galleries and museums, I would always run to the first bench I spotted, because I knew we were going to be there for a while.

I think because I had front-row access to the art world since day one, it definitely took me a little while to truly connect with art significantly. For me, it wasnt until I began my first artistic explorations through acting at 16 that I began to really engage with art. Afterward, I remember going to a small Matisse exhibit at the Jewish Museum in New York, and the paintings moved me in a way that I had never felt before. Each brushstroke was so powerful, and I finally felt a connection.

Sophie, its interesting that you described Gaa as your mentor for this project, instead of your protg. How would you describe your relationship? What have you learned from each other over the years?

Matisse: Gaa is so different from me, but we have a lot of similarities, too. I love her freedom and audacity. Shes unafraid and ready to go out there and conquer, and has been like that ever since she was a kid. I have a lot of admiration for that, and its something Im much slower at doing myself. In certain situations, I ask myself, How would Gaa respond to this?

We both have different elements that we bring to the conversation. I have more experience, but she has a depth of thinking that, in my opinion, is very developed. Were always in touch, and weve always been very tight because her dad [Alain Jacquet] was very busy as an artist, always traveling and spending a lot of time in Paris. It left us together, just the two of us, much of the time. We are very tight, still; she could even be a sister in some ways. Theres a particular closeness there thats not always what you get with kids. But, at the same time, she always felt free to go out and face the world.

Jacquet-Matisse: My mom and I have always been super close. Shes right, it was always the two of us, with my dad being a bit older and living between Paris and New York. Shes always been my best friendand, I think because of how young she is at heart, we were always able to have fun and the best time together in virtually every situation. I feel so lucky to have been raised by artist parents who were so openminded. I was never pushed into doing something I didnt like, and had the freedom to explore whatever I wanted.

Sophie Matisse. Photo by David Lipman.

What are your driving forces as women in the art world?

Matisse: Its important to mention that I really was very inspired by my dad. Hes not in the art worldhes a private artist and inventor, but he wasnt involved in the art scene, per se. He was always making things and making things possible, and it gave me such an incredible feeling of empowerment in the sense that whatever I wanted to do was never out of the question. Anything felt possible.

After my dad, my other major influences would be Marcel and [Henri] Matisseyou cant escape it! If Matisse felt a little heavy-handed, Marcel served as a lightweight, cheerful person to think about. Growing up with my grandmother, who carried and channeled his spirit, was a beautiful experience on a simple and pure level. That was a real blessing, and it gave me permission to stick to art that was close to the heart. Of course, Matisse is always there, like something that is still beating, always alive.

Jacquet-Matisse: My family is a huge inspiration for me. There are so many artists in it, and the way they work with so many different media is really fascinating. Im also inspired by tribal artists from all around the world, and by ancient crafts and objects. Its so beautiful to see what global artisans and cultures have been producing for thousands of years. They have unique senses of color and texture.

Tell me more about your individual artistic pursuits. What are you working on now?

Matisse: Ive been creating stop-motion art films. They contain little storylines with chess pieces as characters, almost. There are no words, but little moments where theres an actual emotional feeling between two pieces. I think its interesting and beautiful, in terms of timing and movement. Its quite fun to doa tedious thing, but very rewarding.

Jacquet-Matisse: I never really got into the arts, aside from acting, but Id say my primary form of artistic expression is fashion. In the past year, Ive created my own accessory line, AA. I play with different textures to create unique, one-of-a kind pieces that celebrate the female form. I really love creating and playing with color.

Aside from AA, I also work as a stylist, wardrobe consultant, and personal shopper, which allows me to play with fashion even more and help people feel more comfortable with themselves. How we dress is an outer form of representation of the self, and even though some would certainly say its on the superficial side of things, when you feel good in what you wear, it affects the energy you put out into the world. Some people have a harder time finding clothing they feel good in, and I love helping them with that.

How do you feel about the idea of striking a work/life balance?

Matisse: I feel like I just stepped out of that mode of feeling that I had to be on it all the time. The pressure from the art world is too distracting; my life is busy as it is.

These days, I choose which openings I attend and how I spend my time more carefully. Art is all around me all the time, and Im constantly looking at things that show up in what I do. Its important to not get too sucked into itto stay grounded and aware of whats meaningful to you, what actually makes a difference in your life. Sometimes that can get a little cloudy. Its important not to let the outside world assume too much control, and to maintain a connection with your inner self.

Jacquet-Matisse: I think its very important to have a work/life balance. Because I dont have a nine-to-five job, I have a lot of freedom to decide how I spend my time. When I dont work for a long period, I feel frustrated, and that affects my personal life. The same goes for when I work too hard during shorter periods of timeit becomes exhausting. Its all about finding a rhythm that works for you, and making sure that what youre working on has some relation to what you love doing in life.

Gaa Jacquet-Matisse. Photo by David Lipman.

What do you hope to see changed in the art world 10 years from now?

Matisse: Its disheartening that some people are drawn to price tags instead of the art itself. Thats a shame. Sometimes you see artworks that go for astronomical prices that dont make sense, and sometimes you see something thats really great sell for a tenth of that price. On the other hand, the money issue has also brought art into a bigger realm, with more opportunities for artists all over the world, which is extremely important. We can learn a tremendous amount from other cultures, and thats wonderful. I hope that the art industry continues to become more and more open, dissolving borders and just letting art and artists exist.

Jacquet-Matisse: Although I am not personally very involved in the art industry, I have seen how things have changed in the past 20 years. With the internet and social media, certain artists have risen to the top very fast, sometimes simply by doing what they know will sell. I hope in 10 years we can go back to the authenticity of the art world of earlier times, before social media and the idea that likes on Instagram equate to someones worth.

What advice would you give young women who are hoping to have careers in the art industry?

Matisse: The most rewarding thing is to make art that resonates with oneself. If you can afford to make art that speaks to your heart, its far more interesting and rewarding than any financial thing. Theres fantastic work being done, and you can tell when its from the heart. Stick to what resonates within you as much as possible, because its a losing battle if you dont.

Jacquet-Matisse: I agree. The most important thing when creating art is to do it for yourself, and to stay true to yourself. When you start making something in order to please an audience, it becomes something completely different.

Photographer: David Lipman

Art Director: Yulu Serao

Stylist: Melena Lipman

Hair Stylist: Rudy Martins

Makeup: Tina Bech

More:

Stick to What Resonates Within You: Mother-Daughter Duo Sophie and Gaa Jacquet-Matisse on How to Thrive in a Changing Art World - artnet News

Sustainable Investing: A trend that’s here to stay – Independent Online

Invest/13 November 2019, 09:00am/Jason Liddle

In less than two months the next decade will be ushered in. While it presents us with an opportunity to examine the decade that passed, it also allows us to look forward and consider which trends will transform the local and global asset management industry.

There is growing consensus that sustainable investing is going to become a mainstream discipline and a key trend in the 20s. Regulators across the world have already set their expectations for the industrys players with requirements of greater transparency, investment process integration and reporting.

Sustainability factors have also shown evidence of enhancing performance within integrated investment processes over those that do not while avoiding risks that may not have been avoided otherwise.

The FSCA clarifies that ESG factors also relate to the advancement of B-BBEE

In June 2019 the FSCA issued Guidance Note 1 of 2019: Sustainability of Investments and Assets in the context of a Retirement Funds Investment Policy Statement. In conjunction with Regulation 28, it states that a fund should considerall factorsthat may materially affect the long-term performance of any asset it invests in. Environmental, social and governance (ESG) factors, alongside economic drivers, do not form the exhaustive list of sustainability factors.

The Guidance Note states that, in respect of domestic assets, ESG factors also relate to the advancement of broad-based black economic empowerment.

The expectations from the regulator are that a retirement funds process will be able to test areas of evaluation, monitoring and active ownership in pursuit of its sustainable investment objectives.

Trustees need to select fit-for-purpose strategies

There are various strategies that can be called on when implementing a sustainable investing framework. Retirement fund trustees will require a complete understanding to select asset managers and strategies that are fit for purpose:

Negative screening:An investor purposefully filters out the companies/entities that they deem to have a negative effect on society. This approach may exclude industries involved in tobacco, thermal coal, arms or gambling. Norms-based screening is related in approach but excludes companies that break international conventions.

ESG integration:This approach is the most commonly used. Traditional investment analysis and decision making at the individual instrument level is augmented with ESG performance indicators. Another related approach, the best-in-class ESG overlay, tilts towards specific ESG scores relative to the overall market or industry peers within a quantitative or index approach.

Thematic investing:As the name suggests a specific sustainability theme is selected, such as climate, housing or water, based on a financial/economic motive or clients need to align the portfolio with their specific values.

Impact investing: This approach places money with entities that intentionally target measurable social or environmental projects with direct impact.

Asset managers need to take active ownership

While the challenges are significant, the leading sustainable asset management practitioners will develop an authentic and credible approach articulating how sustainability is rooted in their investment philosophy. Evidence-based proof of its integration in their investment approach, process and outcomes should support their credibility.

Active ownership is a key area within the framework where engagement, intervention and voting act as the voice of the investor. While comprehensive proxy voting guidelines/policies and a disciplined and robust engagement approach are the table stakes, influence over the decision-making of the companys board is the ultimate desired outcome.

Sanlam has continued to provide a respected voice on behalf of our clients for many years targeting better outcomes. Trustees need to avoid thinly resourced functions that focus more on compliance and instead employ authentic practitioners that drive a mandate to activate, enable and equip investment professionals in making better decisions, using a sustainable investing lens. Sanlam Investments has and continues to invest in new tools and the right talent to harness ESG data and drive our internal research.

Asset managers will also look to differentiate themselves by expanding their ESG investment process reach to all asset classes an important requirement or expectation from the regulator.

PERSONAL FINANCE

Read the original:

Sustainable Investing: A trend that's here to stay - Independent Online

Inside the New Coalition Fighting for Reproductive Justice in the Southeast – Ms. Magazine

The Southeast is the battleground in the latest wave of radical attacks on abortion access. From Georgia to Alabama, and now to South Carolina and Tennessee, we are confronting increasing threats to our safety, bodily autonomy and human rights.

But the Southeast is also home to a diverse, vibrant and growing movement of people and organizations who are coming together to ensure that our society protects and respects the dignity, health and human rights of all peoplein every community across our region.

https://www.instagram.com/p/Bxh-Scsgy3x/

The stakes couldnt be higher. As it stands, South Carolinaranks43rd in maternal mortality and 46th in health outcomes for women. Next door, Georgia has even worse outcomes,rankinglast in maternal mortality with 46 deaths per 100,000 live births. In Tennessee, 85 percent of recent maternal deaths were found to bepreventable; black women in the state are more than three times more likely to die from pregnancy complications than white women.

All across the Southeast, people are suffering, and even dying, because they lack access to reproductive care. Restricting access to abortion only puts more peoples lives at riskespecially folks who already face barriers to healthcare, including young people; people of color; people with disabilities; lesbian, gay, bisexual, trans and queer people; and people living in rural areas. But in each state where abortion threats loom, coalitions are gathering forces and fighting back.

The Southeastern Alliance for Reproductive Equity (SEARE) is a new regional coalition of reproductive health, rights and justice organizations anchored by Healthy & Free Tennessee, SPARK Reproductive Justice NOW!, SisterSong Women of Color Reproductive Justice Collective and the Womens Rights and Empowerment Network (WREN). In collaboration with many other organizations and other state-based and regional coalitions across the region, we are aligning our efforts to strengthen our work across reproductive health, rights and justice. As a multi-racial alliance, we have intentionally rooted our alliance in thereproductive justiceframework, which was created by Black women 25 years ago and demands that all people have the human right to maintain personal bodily autonomy, have children or not have children and parent children in safe and sustainable communities.

We know that to make this vision into a reality in our region, we must work together more collaboratively across geographic and movement boundaries. Crucially, we must diagnose and dismantle systems of white supremacy that perpetuate harm to communities of color and other marginalized people. Through SEARE, we will more deeply reflect on how white privilege affects our organizations, our movements and our communities. We will share our resources and expertise with one another, and we will facilitate closer connections and coordination. We must uplift and invest in innovative grassroots work, particularly work that is being led by people of color, young people, gender-marginalized and other people most affected.

Despite the vocal opposition to abortion bans being voiced across the country, and the majority of Americanssupportingthe right to abortion, legislators across the South are moving quickly to deny people the autonomy to make personal healthcare decisions and access to the resources and services needed to thrive. With the current make-up of the United States Supreme Court, we know that these state-level bills could escalate and set in motion sweeping and severe consequences across the country.

Now is not the time for fear or complacency. Now is not the time for us to retreat to our silos. Instead, it is the time for organized resistance and collective action. With access to abortion under attack like never before, we must come together to speak up.

The South has always had something to say. As a united movement, SEARE will ensure we are heard.

See more here:

Inside the New Coalition Fighting for Reproductive Justice in the Southeast - Ms. Magazine

Santa Cruz Gives 2019: A Guide to Holiday Giving – Good Times Weekly

Share

Share

Share

Email

Last year, giving to nonprofits was up by an average of 4.5% nationwide. But here in Santa Cruz, donations to the nonprofits participating in our holiday giving campaign Santa Cruz Gives grew by 19% in 2018 over the previous year.

The message has come through loud and clear: people in Santa Cruz County care about improving and uplifting their community, and they have chosen Santa Cruz Gives as a vehicle for being a part of that positive change.

So we are thrilled to announce that for 2019, we have expanded the number of local nonprofits accepted into the campaign. In previous years, we were wary of growing too fast, and overreaching beyond what this fledgling charitable project was capable of sustaining.

But you have sustained this effort, and driven it far more quickly than we imagined when we first conceived it. If we reach our goal of raising $300,000 between now and the end of the campaign at midnight on Dec. 31, then Santa Cruz Gives will have raised more than $1 million for local nonprofits in its first five years. That is an incredible testament to the spirit of giving in Santa Cruz County.

The bold growth of this program would not have been possible without our partners at the Volunteer Center of Santa Cruz County and Community Foundation Santa Cruz County, and our business sponsors Santa Cruz County Bank, Wynn Capital Management and Oswald.

Most of all, it would not be possible without you. So please give generously to our participating nonprofits. Read about all of them hereboth their mission statements and the projects they will fund with the money raised through Santa Cruz Givesthen go to santacruzgives.org, our easy-to-use website that lets you give conveniently and securely to all of your favorite causes.

Organization Mission: We create and support one-on-one mentoring relationships that ignite the power and promise of youth. We have served more than 7,000 local at-risk children, providing a crucial foundation at a critical time in their lives. Mentors make Santa Cruz County a safer and healthier place by helping children make better decisions, which increases their chances of staying in school and decreases their challenges with substance abuse, teen pregnancy and the criminal justice system.

Transgender Matching Program and LGBTQ+ Service Expansion

Our local agency, Big Brothers Big Sisters of Santa Cruz County, is the first and only agency in the entire nation to have a Trans Matching Program. We began matching transgender youth with volunteer transgender adult mentors in 2015. The program now serves as a national model.

Using our proven mentoring model, volunteers receive in-depth training on how to support these youth, who routinely face pervasive injustice, bias and mental illness in their daily lives. Research shows a quality mentoring relationship reduces the risk of suicide in the trans population by 50%.

We want to expand our efforts in the LGBTQ+ arena through training, roundtables and enhanced match support for all of our mentors, our matches and for other youth-serving organizations in the community. Discrimination and bias often begin in childhood, as LGBTQ+ youth explore their gender identites. They are at high risk of harassment, physical and sexual violence, and suicide. We work with this underserved population in close partnership with other agencies.

We grasp that gender identity can be fluid, and providing deeper support for all LGBTQ+ program participants will improve outcomes for youth we serve. Our volunteers are trained when first matched, and many matches last for well over five years. We must update our training so that long-term volunteers are prepared.

Organization Mission: The Bird School Project aims to inspire and equip both students and teachers to love, study and steward their local environment.

Creating Leaders for the Environment

In 2020, Bird School Project aims to unify youth leadership around a vision for lives that are relaxed, mentally resilient and less distracted.

The Bird School Project provides educational experiences to students directly on their schoolyards, making nature and a bit of wilderness easily revisited, leading to appreciation, inquiry and stewardship. Students grow an appreciation for the unexpected and a love for nature.

The main goal is to deliver a four-week, eight-lesson life science unit on birdingincluding guided, on-campus bird walks; use of binoculars; close examination of museum specimens; and the use of a field journal in which students learn to record their observations creatively.

Students build skills in focus, direct observation, meaning-making, arguing from evidence, and collaborating with peersand benefit further from the research-based, proven healing effects of time spent outdoors. Observations of real-time happenings in nature generate a sense of connection with other living organisms and lower stress about school, peer groups or family life among diverse youth.

We provide programming countywide, but focus in the Pajaro Valley on middle school students. Their school schedules allow for few opportunities for field trips, and programs like ours are needed to connect students with their environment.

Organization Mission: CASA of Santa Cruz County advocates for children, providing court-appointed volunteers so each child in the Dependency Court system feels cared for and connected with the people, families and resources they need to heal and flourish into adulthood. CASA empowers volunteers to directly influence life-changing decisions affecting children in dependency (foster) care.

Be the Voice for a Child in Foster Care

CASA of Santa Cruz is seeing more children under the age of 3 entering the foster-care system. This is where CASA comes in: We recruit, screen, train, and supervise volunteer advocates to work one-on-one with children and their families to support reunification or permanent placement into a safe and healthy home. Advocates get to know their childs situation and needs, help caregivers access resources to meet those needs, and advocate for the childs best interests in court, community and school settings.

They build strong relationships with the family and work with a CASA advocate supervisor to create an advocacy plan for their child. They provide regular reports to the court, which the judge relies upon to inform life-changing decisions for children in foster care.

Our advocates understand that children experience great trauma as a result of entering the foster care system, provide them with a warm layer of support, and connect them to resources to benefit their development and well-being. CASA is the only organization with volunteers officially sworn in by the court, acting as advocates for our areas youth.

When a case opens in Dependency Court, the focus is on the parents/caregivers gaining resources to help meet their case plan, but a CASA volunteer focuses on the child. While they may support the entire family, their priority is the child. Advocates are assigned to the childs case until the child is placed in a safe, permanent home and the case is dismissed.

CASA children have a higher rate of adoption than those without an advocate, are less likely to return to the system, are substantially less likely to spend time in long-term foster care, and are more likely to become healthy adults who break the cycle of abuse.

Organization Mission: The Coastal Watershed Council was formed to address the declining health of watersheds connected to the Monterey Bay National Marine Sanctuary, with a mission to preserve and protect coastal watersheds through community stewardship, education and monitoring. Since 1995, CWC has educated thousands of volunteers and thousands of students to monitor water quality, enhance habitat and protect the natural resources along our Central Coast.

San Lorenzo River Health Days

Santa Cruz formed because of the San Lorenzo River. The river remains our primary drinking water source, and is designated as a critical habitat for threatened and endangered species of fish.

Most locals agree that our community deserves a healthy river ecosystem surrounded by safe and inviting parks. With your help, we can make further progress toward a vibrant riverfront.

CWC is asking for support for River Health Days. We will engage volunteers, including youth groups and corporate teams, to remove invasive species and replace them with native plants.

In addition to improving ecosystem health, these community work days reintroduce families and youth to the river through meaningful, positive experiences in nature. Last year, 674 CWC volunteers contributed 1,782 hours of work and planted 2,120 native plants, replacing 6,450 square feet of ice plant.

Organization Mission: Community Bridges envisions a thriving community where every person has the opportunity to unleash their full potential. We believe that when we work together, anything is possible. Our family of 10 vital programs across 20 sites meets the needs of nearly 20,000 local children, families and seniors each year with essential services, equitable access to resources and as advocates for health and dignity across every stage of life.

Food Stability for Homeless Seniors

In 2017, 39% of homeless people in Santa Cruz County were over the age of 50, and 70% of homeless deaths were people over the age of 50. For the past five years, Meals on Wheels (MOW) for Santa Cruz County, a program of Community Bridges, has seen an increase in homeless senior participants at Louden Nelson Community Center.

While MOW has been providing meals five days per week to eligible older adults (more than 650 warm, nutritious meals per week), to address food insecurity among the vulnerable homeless population, we have begun to assemble weekend meal packs that provide at least two nutritious meals.

We are asking Santa Cruz Gives donors to join MOW efforts to ensure that no senior goes hungry, and support our goal to ensure that homeless seniors attending Louden Nelson will have nutritious meals on the weekends in 2020.

Funding will provide participants two shelf-stable mealsmeals they will not be able to receive otherwise because most dining facilities are closed on weekends.

Organization Mission: To create lasting oral health for underserved children and adults.

Give Kids a Smile Day

There is nothing quite like a toothacheit is all-consuming. Toothaches are the most common reason low-income children miss school, and theyre largely preventable. You can help make prevention more common than treatment, so that children are able to focus on school instead of a toothache.

Give Kids a Smile Day provides free dental care for uninsured kids who would otherwise fall through the cracksfamilies who dont qualify for public insurance and cant afford expensive or even discounted dental care. The need in Santa Cruz County is huge. Two out of three people with public insurance (and many more low-income, uninsured residents) are not receiving dental care.

Dientes aims to create healthy habits and positive experiences with the dentist. With your generosity, we can prevent expensive treatment in the future and help kids continue good oral health throughout life.

Your support is needed to get rid of toothaches, so local kids can get back to being kids.

Organization Mission: Farm Discovery empowers youth and families to regenerate healthy food, farming, nature, and community in the Pajaro Valley. We improve personal and community health and our impact on the Earth by building collaborative agricultural, ecological and social systems.

Farming and Environmental Education Internship for Local Young Adults

Many local farms cannot find skilled labor locally and must hire workers from outside the area, even while the Pajaro Valley is home to the largest family-owned organic farm in the U.S. In addition, our most food-insecure members often work in agriculture or are the children of agricultural workers.

We address both issues by offering Santa Cruz County youth an opportunity to learn to grow healthy food through a 10-month paid internship that inspires them to pursue careers in agriculture or environmental education. The students gain a unique set of skills aligned with Next Generation Science Standards.

Interns will spread their knowledge in the community by teaching thousands of local youth through our field trips and summer camp programs, passing on the skills to grow their own produce, along with cooking and preserving, tackling two major skill sets to benefit younger students and their families.

The interns finish the program with various levels of mastery of skills, such as propagation, cultivation, soil fertility, pest management, and post-production that Farm Discovery is uniquely suited to provide with access to Live Earth Farms 150 acres of organic productionan inspiring learning space.

Organization Mission: Food, What?! is a youth empowerment and food justice organization. At FoodWhat, youth cultivate their well-being, liberation and power by engaging in relationships with land, food and each other. Youth from Watsonville to Santa Cruz join the FoodWhat Crew through our spring internship, summer job training and fall project management programs. Within the supportive space of FoodWhat, youth grow, cook, eat, and distribute farm-fresh, organic food while addressing local food justice issues.

Youth-Powered Farm Stand For Community Health

In our project, FoodWhat youth gain real-life work experience by running a prescriptive farm stand in partnership with Salud para la Gente and Lakeside Organic Gardens. Salud health care providers prescribe patients with diabetes a voucher to the youth-run farm stand stationed right outside the clinic.

Some of the produce at the stand is grown and harvested by FoodWhat youth, and some is donated by our partner farm. At the farm stand, clients choose from an abundant selection that includes rainbow carrots, broccoli, chard, cucumbers, cauliflower, peppers, and tomatoes.

We cannot overstate the importance of this aspect: Local youth combine training with their lived experience to address needs in their own neighborhoods.

The new project increases FoodWhats distribution by over 2,000 pounds to those with the highest need, and is an opportunity for youth to support patients as they build strong habits around accessing healthy food, integrate this food into their familys diets, and create a community space at the intersection of youth power and community health.

Organization Mission: To inspire all girls to be strong, smart and bold, and to respect themselves and the world around them. Girls Inc. serves 1,700 girls in 41 schools with trained professionals (often older teens), who mentor them in a safe environment. Girls are inspired to pursue secondary education, develop leadership and decision-making skills, serve their communities, and acquire the ability and wisdom to lead healthy lifestyles.

Growing Together

The relationship between a girl and her mother is so powerful, it affects everything from her health and self-esteem to setting the stage for all relationships throughout her life. Communication can be a common challenge for young girls and their mothers. As girls go through puberty and related physical, mental and emotional changes, the challenges can escalate.

We hope to assist by supporting girls and their mothers or another significant adult with our new program: Growing Together. Its designed to increase positive communication between girls ages 9-12 and their mothers, or possibly a sister, aunt, grandmother, or father.

Your gift will support girls in Santa Cruz County for a weekly get-together for four weeks to share activities aimed at learning about values, body changes, health and hygiene, nutrition and exercise, goals, problem-solving strategies, conflict resolution and positive communication.

Girls Inc. teaches girls to set and achieve goals, boldly confront challenges, resist peer pressure, see college as attainable, and explore nontraditional fields.

Organization Mission: Local and vital, Grey Bears promotes nutrition, activity and social connection as a recipe for healthy aging. Our vision is that all seniors live healthy, meaningful lives. Grey Bears has evolved into one of the most efficient and resourceful food distribution, reuse and recycling nonprofits in the U.S.

Engage at Every Age

Grey Bears is a nutritional lifeline for 3,800 low-income seniors, families and veterans, delivering weekly brown bags full of fresh produce and healthy staples to Santa Cruz County aging adults. Additional daily food distributions and 40,000 hot meals served annually nourish thousands more. It all adds up to more than 2 million pounds of food distributed each year.

Hundreds of volunteers enjoy more than 20 volunteer opportunities. Their service makes our programs possible while cultivating social support systems and health benefits for both volunteers and participants. Weekly classes include tech help, Spanish, cooking, chair yoga, fix-it clinics, and luncheon events designed to keep seniors active and socially engaged, and help them age with joy, grace and dignity.

Organization Mission: Groundswell restores coastal ecosystems using nature-based solutions. We are a constructive group of ecologists, naturalists, educators, and community dedicated to designing and building habitat that makes our coast better for nature and people. We prioritize restoration that increases biodiversity, coastal resiliency, and expands community outreach. We harvest local seeds, grow native plants, then plant at degraded habitats in need of stewardship. We are small but mighty, making this work happen by pulling together an amazing group of committed volunteers, teachers and K-12 students from all over Santa Cruz County to participate in the full cycle restoration process. Groundswell has rebuilt habitat resources and restored over 11% of the Santa Cruz coastline, including well-loved beaches like Seabright, Natural Bridges and Davenport Landing.

Saving Santa Cruz Monarchs

Monarchs are on the verge of collapse, and have declined 99% on the West Coast since the 1980s. Santa Cruz is a monarch hotspot where Lighthouse Field State Beach Park is home to the second-largest overwintering population of monarch butterflies in California.

To save Santa Cruz monarchs, we want to continue to lead the community in enhancing this critical habitat. We can do this together by building nectar resources, optimizing overwintering grove conditions and curbing predation. We steward the grove ecosystem and have led students and community volunteers in this effort.

We need your help to continue this critical work, as well as to expand to other overwintering sites in Santa Cruz. Monarchs are at the heart of our community and an important part of our tourist industry.

Organization Mission: Our Mission: In the soil of our urban farm and garden, people find the tools they need to build a home in the world. Our Vision: We envision a thriving and inclusive community, workforce, and local food system. We Value: The capacity of every individual for growth and renewal, the joy that comes from growing and sharing healthy food, the well-being created by vibrant social and natural ecosystems.

Two Steps Closer to Home

The Homeless Garden Project (HGP) is building a new, permanent home, Pogonip Farm. Located within the City of Santa Cruzs Pogonip greenbelt, our new 9-acre farm will triple our capacity to transform lives and build community connections. Serving as a national model, Pogonip Farm will be the heart of HGPs dynamic agriculture program for people who are experiencing homelessness. We help to transform lives by finding homes, providing job training, teaching skills, providing volunteer opportunities, and stewarding land through organic farming.Last year, 100% of our trainee graduates obtained stable employment and stable housing, and more than 7,000 pounds of fresh, organic produce were distributed to nonprofits throughout Santa Cruz County, feeding 2,500-plus people. Strong bonds are formed by our community of volunteers, interns, customers, and trainees that break down the profound sense of isolation felt by many people experiencing homelessness.

Please consider making a gift toward one-time costs to build the Farm Center at Pogonip: an administrative and kitchen building, a barn, and greenhouses.

Organization Mission: Homeless Services Center partners with individuals and families to create pathways out of their homelessness into permanent housing.

Youth Rapid Re-Housing

The number of young adults experiencing homelessness in Santa Cruz County has grown more than 30% in the past two years. Many homeless young adults were emancipated from our foster care system, and have little or no familial support.

Imagine prepping for your first day of school or a job interview without a place to call home. With your support, we can help 100 homeless young people ages 18-24 get off the streets and into permanent housing.

All of our programs operate with a housing-first methodology: to quickly move people experiencing homelessness into permanent housing, while providing support and services to help them stay housed as they work on achieving goals. Our programs save the county millions of dollars in emergency services every year, while also saving lives.

We believe our community is innovative enough, committed enough and compassionate enough to build a future in which every young person has a home. Your gift can help us guide more youth to develop good lifetime habits.

Organization Mission: The all-volunteer Live Like Coco Foundation helps local kids grow up healthy and with opportunities to pursue their dreams. Our foundation is named for and inspired by Coco Lazenby, a self-described book lover, cat petter and environmentalist, who was killed in a car accident in 2015 at age 12. To honor Cocos bright spirit and big heart, our foundation works in four areas that made a difference in her life: literacy, nature, health and wellness, and funding for extracurricular activities.

Continue reading here:

Santa Cruz Gives 2019: A Guide to Holiday Giving - Good Times Weekly

5 Things I Wish Someone Told Me Before I Became an EVP with Fiona Bruder, of George P. Johnson (GPJ) – Thrive Global

Never stop learningleaders learn every single day, we all do. Remaining humble, seeking guidance when needed, and appointing or delegating others with expertise is critical to ongoing growth as an individual and a collective group. The smartest leaders hire smart people and place them in roles that will enhance the success of theteam.

As a part of our series about strong female leaders, I had the pleasure of interviewing Fiona Bruder.Fiona is the Executive Vice President of Client Success George P. Johnson (GPJ). With nearly 30 years of experience, Fiona is a seasoned marketing executive and expert in experiential marketing and program development. Based in New York, she manages a team of marketing leaders in more than 34 countries and is responsible for overseeing and managing the agencys key global accounts, including IBM, Redhat, Facebook, Macys and AMEX while leading GPJs offices in Boston, New York City, and Austin. Fiona is proud to serve as executive sponsor of the GPJ Women Employee Resource Group (ERG), one of the employee-led groups that foster a diverse, inclusive workplace aligned with organizational mission, goals, and business objectives. She is also a dedicated ally to the House of GPJ, the companys LGBTQ+ ERG. Since joining GPJ nearly 20 years ago, Fiona has created, produced, managed and optimized event portfolios for some of the worlds leading brands including, IBM, P&G, MasterCard, Conduent, Jaguar Land Rover (JLR). She is an active member of the Forbes Agency Council and outside the office, Bruder serves on the board of directors at Girls Inc. Westchester, a 100-year-old organization that inspires girls to value their whole selves, discover and develop their inherent strengths, and receive the support they need to navigate the challenges they face.

Thank you so much for doing this with us! Can you tell us a bit about your backstory? What led you to this particular career path?

Having graduated from Fordham University with an MBA in Marketing, I had an idea early on of what I wanted to do in this industry. When I started out, event marketing was not its own category yet, as marketing at large certainly was not what it is today! Nevertheless, the one thing that has remained a constant imperative, despite the shifts across the industry and changes throughout society, is human engagement. In order to be successful, you must have a clear understanding of how people interact, learn and engagewhen you combine all of these elements, you get the recipe for what we do here at GPJ with experiential marketing.

Its the ongoing focus on human engagement that drives my perpetual dedication to this business, especially since experiential gives us the ability to create an environment that offers a multi-layer impact. From the bottom line of the business, to the industry at large, to society as a wholethe work we do truly matters. Quite a few of our clients at GPJ parallel our legacy and tenure in the business, and like us, such brands have the symbiotic ability to continually reinvent and remain ahead of the curve at every touchpoint. We are constantly challenged to stay at the cutting edge and have developed the ability to reinvent ourselves and our industry while creating things that have never been done before.

What is it about the position of vice president that most attracted you to it?

First and foremost, I have profound respect and loyalty for GPJ, and having been here for more than 18 years, its where I have laid a large part of the foundation of my career. We started as a family business and grew into an employee-owned enterprise that does groundbreaking work across the globe. We are offered unparalleled autonomy and empowerment within our careers; at GPJ, the people, our diverse backgrounds, and each unique viewpoint are encouraged and welcomed. Moreover, our global staff has exceptional cultural intelligence that allows us to both think big and execute locally relevant programs, and with this, we continue to be afforded the opportunity to create over and over again.

Ive remained passionate about my career growth largely because of my desire to optimize my effectiveness across the board and create a platform for others to grow and advance as well. As a female leader at my company and industry, I have the opportunity to elevate other diverse voices, invest in robust company culture, and create tangible change in our industry.

Most of our readersin fact, most peoplethink they have a pretty good idea of what an executive does. But in just a few words can you explain what an executive does that is different from the responsibilities of the other leaders?

The most effective executives continuously challenge themselves while holding the responsibility of looking at the business from every anglethe marketplace, clients, strategy, culture, and so on. Leaders are charged with maintaining homeostasis across the business while making incredibly difficult decisions. Its the art of balance. Internal success is one thing, but its important to note that were also responsible for keeping our finger on the pulse of larger trends within business operations, our industry, and society as a whole. This means constantly learning, putting yourself out there by asking questions, and remaining open to constant growth. The opportunities to learn are everywhere for me, whether thats through trade shows, at conferences, or through travelI take the key learnings and act on them. I also ensure I share what Ive learned with others along the way (whenever applicable).

As a leader, fluency in all aspects of the business is critical, but even more important is putting the right people in appropriate disciplines to elevate skills and satisfaction. Notably, only the strongest leaders will hire the smartest people in the room. Even though an executive may spend a great deal of time focusing on bottom-line results, its imperative not to lose sight of the creativity that is built within the DNA of the work. The most strategic aspect of being an executive is to study all angles and potential impact of stakeholders, and then be decisive. Every second of every day involves vital decision making, tough decisions most often, and then course-correcting as needed.

What is the one thing that you enjoy most about being an executive?

I enjoy the autonomy to make my own decisions and the authority to help people break through the noise. In my position, I am privileged with the ability to elevate peoples voices, concerns, and work, and certainly, the easiest part of my job is providing this type of support and encouragement! Its always my goal to raise others up, so I will encourage individuals to step out of their comfort zones to show them their maximum potential. When leaders do this, it is essential to create a safe environment for employees to pressure test their abilities. Its amazing what people can accomplish when given the confidence and opportunity to challenge themselves and embrace and learn from their mistakes.

What are the downsides of being an executive?

The downside is timeexecutives would be quite pleased if there was a way to control time throughout the business day. Prioritizing is key because the to-do list does not endthere will always be something to do because that is the nature of our roles. Leaders drive change and impact. Its what we should expect and quite frankly, enjoy! By motivating others and creating a highly productive work environment where people feel valued and satisfied to come to work, youll see results come to life. Be patient though, and know that if you really want to motivate someone, you first must understand what makes them tick.

What are the myths that you would like to dispel about being a CEO or executive. Can you explain what you mean?

Someone once told me before a large speaking engagement that I appear as if Im never nervous. I think this is a common misconception about executives or business leaders. Its my job to make our employees feel confident, and of course, there are moments when nerves set in, but an unspoken part of the job is to remain a steady hand under pressure. Were in such roles to make tough decisions, to put ourselves out there, and to remain calm, cool, and collectedthats what the job requires.

Another misconception is that when making decisions, executives dont take all parties into account. The reality is, every decision is based on what is best for the greater good of the company, the people who make up the company, and the stakeholders. The people are at the core of every decision.

In your opinion, what are the biggest challenges faced by women executives that arent typically faced by their male counterparts?

The unfortunate truth is that women typically face more scrutiny in the workforce than their male counterparts. Every frustration, challenge, or let down may transform into an opportunity to be perceived as emotional. Contrarily, men in high-rank positions who demonstrate decisiveness are praised for their ability to lead and delegate. When men lean into their emotions, they tend to be embraced for their empathy. For example, not too long ago, a female political leader was deeply criticized for showing emotion while an iconic male political figure became even more adored when he shed a tear. Absent of any bias, working in facts alone, its evident that there is somewhat of a reaction safety net for men that isnt quite there yet for womenthough its being built!

Women are under unique pressure to keep their professional image top-of-mind at all times, and while weve come very far, we havent reached equality yet (we will certainly get there though!). In reality, there is no one correct way to operate in business. Weve seen problematic behavior stemming from male-dominated industries, giving rise to movements like #MeToo, #TimesUp, and beyond, and assumptions behind leadership tactics are always changing. There is room for leaders to be vulnerable, for emotionally intelligent solutions to problems, and for plenty of women in leadership roles.

Can you share the most interesting story that happened to you since you began leading your company?

I think the best experience I have had in my career at GPJ was partnering with IBM to launch their first presence at SXSW. It was a non-traditional experience and full-on takeover. We partnered with the executive team to define a new standard for success, address how the IBM brand would show up in this type of environment, and build a concept that would engage a new audience. I remember the moment we realized there was a line around the block and we were absolutely giddy that we had just experienced a new level of success!

Can you share a story about the funniest mistake you made when you were first starting? Can you tell us what lesson you learned from that?

No one is perfect, we all make mistakes, and as youll see in my favorite quote belowits not about the mistake or failure, its about how you get back up, how you rebound, and how you apply the lessons learned in the most effective way.

Years ago, while here at GPJ, we were expanding globally and we were so focused on consistency that we were pushing a local message into a foreign market. The foreign team clarified that our message had a very different meaning and intent when translated, and would be offensive to the audience. It was a lesson I learned earlyengage the markets, understand cultural nuances, gather input, and re-calibrate as needed. When disseminating critical messages to target audiences, its not only about cultural intelligence and being business savvy, its also important to consider regional and local impact as well.

What is the most striking difference between your actual job and how you thought the job would be?

Looking back from when I started years ago, the industry was starkly different. The competitive landscape, the role of events in marketing, the actual definition of an event! Throughout this evolution, society and culture have transformed in tandem. I always had a vision for success and mentorship. I intended always to lead with confidence and humility, and to work for an employer that supported and embraced diversity and inclusivity. Im not quite sure I knew, to the extent, how valued my voice would be, how valued every voice would be, and how engaged the world would become.

The value of personal connections, relationships, and most of all, communicating effectively while ensuring all parties feel supported and heardespecially at GPJ, is absolutely unprecedented.

I knew when I joined GPJ I was working somewhere special, but to also have benefits like Employee Resource Groups (ERGs) for women and for LGBTQ, ownership of the company through our ESOP (Employee Stock Ownership Plan), and endless ability to create as a global teamthis has been an absolute joy to witness unfold and to be a part of.

Certainly, not everyone is cut out to be an executive. In your opinion, which specific traits increase the likelihood that a person will be a successful executive and what type of person should avoid aspiring to be an executive?

There are definitely key attributes that are innate within leaders, such as a desire to lead and empower; a persistent thirst to learn and grow; an ability to communicate, inspire, be decisive, and own accountability; and a passion for excellence that cannot be compromised. When an individual has these qualities, its likely he or she will enter a leadership role at some point in their career. On the contrary, for people who avoid teamwork, speak and rarely listen, and strive for success on an individual scale without integrating the greater group into the missiona permanent leadership role may be difficult. Though, its never too late to change!

What advice would you give to other women leaders to help their team to thrive?

Every role and company is different and every person is unique, so there is not a one-size-fits-all answer, rather, there are several pieces of advice Id love to share:

Always act in the way youd like to be perceivedif you see yourself as a leader, act as a leader. Be respectful, listen, learn, mentor, and communicate with as little doubt as possible, and assume your role as leader.

Find your passionwork life balance is always going to be a challenge, especially for women. To help mitigate the struggles we face here, try to find a job and position that you are truly passionate about. If you do this, youll go to work everyday feeling satisfied and fulfilled, and ideally will be able to create a solution that amplifies the balance in your personal and professional life.

Never stop learningleaders learn every single day, we all do. Remaining humble, seeking guidance when needed, and appointing or delegating others with expertise is critical to ongoing growth as an individual and a collective group. The smartest leaders hire smart people and place them in roles that will enhance the success of the team.

None of us are able to achieve success without some help along the way. Is there a particular person who you are grateful towards who helped get you to where you are?

That would be, Maureen McGuire, the former Vice President of Integrated Marketing Communications at IBM. She was my client early on in my career and she held such a great balance of being an engaging and empathetic leader while assuming her leadership role in an authoritative and direct way. She commanded a room, leaving every meeting or seminar with each person feeling like they had a personal discussion with her, and she challenged her team and agency to push outside of their comfort zones. I have often thought of her approach to leadership and how to apply those lessons to my work.

How have you used your success to make the world a better place?

Not only have I personally focused on this, I am fortunate enough to work for an employer that embraces philanthropy and offers a wide range of programs for which our parent company, Project Worldwide will even match contributions and efforts for, around a multitude of causes. Supplemental to our philanthropy, we have also launched Employee Resource Groups (ERGs) as a part of our ongoing diversity and inclusion mission. ERGs are formed by employees based on topics and issues they feel are most pertinent. Once formed, employees request an executive sponsor to support the group through various initiativesI am the executive sponsor for GPJ Women and the LGBTQIA group.

In addition, outside of the office, I have had the pleasure of serving on several school boards including the PTA (Pleasantville), Pleasantville Community Scholarship Fund, and Pleasantville Fund for Learning. I also serve on the board of directors at Girls Inc. Westchester, a 100-year-old organization that inspires girls to value their whole selves, discover and develop their inherent strengths, and receive the support they need to navigate the challenges they face. Most recently, I held storytelling training with a group of Girls Inc. members and helped them develop their narrative and presentation skills for the annual gala.

What are your 5 Things I Wish Someone Told Me Before I Started and why? (Please share a story or example for each.)

You are a person of great influence. If you could inspire a movement that would bring the most amount of good for the greatest number of people, what would that be? You never know what your idea can trigger.

It would be a global empowerment movementinspiring girls across the world to be strong, courageous and bold and to relentlessly gain the most valuable asset: knowledge. We need to commit as leaders to embrace and empower our young women and create equal opportunities for them in our organizations.

Can you please give us your favorite Life Lesson Quote? Can you share how that was relevant to you in your life?

Vince Lombardi said, Its not whether you get knocked down, its whether you get up. I love Vince Lombardi, not just because I am a Fordham alum, but because he has always summed things up in a simple and honest way (In great attempts, it is glorious even to fail). For me, Lombardis message is all about resilience. You can not learn unless you are willing to fail. This is something I always embraced and also have encouraged with my team.

Note from editor: We are very blessed that some very prominent names in Business, VC funding, Sports, and Entertainment read this column. Is there a person in the world, or in the US with whom you would love to have a private breakfast or lunch with, and why? He or she might just see this if we tag them

First lady or not, I would still love to have lunch with Michelle Obama. Ive had the pleasure of seeing and hearing her speak and have also read her bookthis woman is truly focused on positive change. She used the cards she was dealt to make the most of every opportunityleveraging her and her husbands platform to drive change for education, healthier children, and female empowerment.

Thank you for these fantastic insights. We greatly appreciate the time you spent on this.

More here:

5 Things I Wish Someone Told Me Before I Became an EVP with Fiona Bruder, of George P. Johnson (GPJ) - Thrive Global

Anxiety, depression and the new science of psychedelics part two – ABC News

Norman Swan: Hello, and welcome to the Health Report with me, Norman Swan. Today, part two, a really special conversation with American writer and journalist Michael Pollan on his journey with psychedelics and the promise they might hold for treating addiction, depression, the distress of terminal illness and maybe even creative block.

Last week we covered a part of the brain called the default mode network. Effectively the traffic manager in our brain, our narrative self, our ego, which goes quiet when you take psychedelic drugs. And that's key to understanding the entire psychedelic experience and how it is that some people can report having mystical, life changing experiences with drugs like LSD or magic mushrooms.

But there are risks in taking psychedelics as well, especially when they are done recreationally and without a guide. These include precipitating the onset of psychosis and maybe even schizophrenia. Now Michael Pollan shares his own experiences with these drugs and the changes they wrought in his life, plus future directions for psychedelic medical research.

And a few warnings, this program does have some frank discussion of drug use and some explicit language. The drugs we are discussing are illegal in Australia and in many other countries.

The conversation was recorded in front of a live audience at the Sydney Opera House in July.

Michael Pollan: Most of my experiences were really good, better than I expected them to be. I just didn't know what was going to come up. I was really afraid of discovering, I don't know, childhood trauma or something. I needed to do this to understand and write about it. It's the journalism I do, I like to do participatory journalism. When I wrote about the cattle industry I bought a cow. When I wrote about architecture I built a house. So my readers expect it, so I did it for them. But I also did it because I had started interviewing these volunteers. And the first group I interviewed were these people who had cancer, many of them terminal, who were being given the drug, not to treat their cancer obviously, it doesn't do anything for your cancer, but to help them deal with their anxiety, depression, fear. And their stories were so amazing, the kinds of spiritual breakthroughs they were having, the kind of reset of their minds made me incredibly interested to try it. I had never had a spiritual experience, I don't think I had ever had one, and I was kind of jealous of these people.

Norman Swan: And with the people with terminal cancer, it apparently only worked if you did get some ego dissolution and a mystical experience and you needed that.

Michael Pollan: Yes. There was a real one-to-one correspondence. So they were measuring something called mystical experience. The psychologists have a survey for everything and a score for everything, so they've actually quantified the mystical experience, and it has thesethere are eight characteristics, one is ego transcendence, another is unitive consciousness, that you are joining with something else, another is transcendence of space and time, you know, they have this list. And the people who had had what's called a complete mystical experience were the ones that had substantial reductions in their fear and depression around death.

I'll give one example of a woman who had a remarkable story. She had ovarian cancer, she was about 60, she was a figure skating instructor in Manhattan named DinaBazer. Her cancer had been treated, it was in remission, but she was paralysed by the fear it was going to recur at any time, that the other shoe was going to drop, and she couldn't do very much. And she entered this trial, had the careful preparation session with the two guides, and then the guides were with her during the whole journey, which lasted about five or six hours.

And like a lot of the cancer patients, her experience took her inside her body. She had this experience of travelling inside her body. Many of the cancer patients had a confrontation with their cancer. In her case though she sees a black mass under her rib cage. So she knows it's not her cancer, it's in the wrong place, but she recognises it immediately and she knows it's her fear. And she's spontaneously screams at it. Now, imagine these two guides, they don't know what's going on in her head, and suddenly she says, 'Get the fuck out of my body!' And with that, it vanished, the fear vanished.

And I wrote this in a piece I wrote for the New Yorker about this particular trial, and in the measly way of journalists trying to thread the gauntlet of fact checkers I said her fear was substantially diminished. And they called her and they read it to her and she said, 'No, he got it wrong, it's totally wrong, my fear was extinguished, completely eliminated,' which is the most remarkable thing.

Norman Swan: Is this the woman who was an atheist?

Michael Pollan: Yes. She also had told me before that she was an atheist. I said, 'What happened after you got rid of your fear during the trip?' She said, oh, it was the most amazing thing and this happened and this happened, and I kissed the face of God. And I said, 'But you told me you were an atheist. Are you no longer an atheist?' And she said 'No, I'm still an atheist.' And I said, 'Well, how can you kiss the face of God?' And she said, 'We don't have a word big enough for what happened. God is the biggest word we have for this kind of experience, so I have to use it, but I'm still an atheist.'

Norman Swan: So brieflyI mean, we haven't got time to go through everything, but where did you rate on the mystical scale and did it change according to setting and drug?

Michael Pollan: You know, for me I did fill out the mystical experience questionnaire because I wanted to see if I scored

Norman Swan: 'How well did I do?'

Michael Pollan: And on two of my trips I did I had complete mystical experiences. Interestingly enough, one was incredibly positive and one was incredibly negative, but in both cases I had transcendence of space and time and unit of consciousness, all this kind of stuff. And the bad one was really horrifying.

Norman Swan: So that was DMT, the toad.

Michael Pollan: Yes, so this was a pretty obscure psychedelic that wasn't on my agenda, and it's not being researched in a serious way, and it's called 5-MeO-DMTnobody is clapping for it, okaythis is the smoked venom of the Sonora Desert toad. A species that figures that out has got something going for it. So I had this opportunity, one of my sources said that this person who was coming up from Mexico who collects the venomand by the way, no toads are harmed in the making of this psychedelic, you just gently squeeze these glands and it shoots this liquid onto a piece of glass

Norman Swan: We're taking notes and now, are we

Michael Pollan: Well, you've got to find the toads, you're not going to find them in Australia. And then it crystallises and then you smoke that crystal. So I had the opportunity to do this and I really was afraid of it. I had interviewed somebody who had used it, an acquaintance of mine, and we were having lunch together and she reaches across and she puts her hand on my forearm like this and she said, 'It's the Everest of psychedelics.' And I was really scared about using it. All my experiences I had a sleepless night before as my ego essentially tried to convince me not to assault it with a chemical, and this one I did too, but I did it. And if you'd like I can read a passage about it, about this trip, which illustrates how bad things can get but also some of the challenges of writing about this.

So you take one long puff from this pipe andwell, I'll begin with this:

I have no memory of ever having exhaled, or of being lowered onto the mattress and covered with a blanket. All at once I felt a tremendous rush of energy fill my head accompanied by a punishing roar. I managed, barely, to squeeze out the words I had prepared, 'trust' and 'surrender'. These words became my mantra, but they seemed utterly pathetic, wishful scraps of paper in the face of this category 5 mental storm.

Terror seized meand then, like one of those flimsy wooden houses erected on Bikini Atoll to be blown up in the nuclear tests, 'I' was no more, blasted to a confetti cloud by an explosive force I could no longer locate in my head, because it had exploded that too, expanding to become all that there was. Whatever this was, it was not a hallucination. A hallucination implies a reality and a point of reference and an entity to have it. None of those things remained.

Unfortunately, the terror didn't disappear with the extinction of my 'I'. Whatever allowed me to register this experience, the post-egoic awareness I'd first experienced on mushrooms, was now consumed in the flames of terror too. In fact every touchstone that tells us 'I exist' was annihilated, and yet I remained conscious. 'Is this what death feels like? Could this be it?' That was the thought, though there was no longer a thinker to have it.

Here words fail. In truth, there were no flames, no blast, no thermonuclear storm; I'm grasping at metaphor in the hope of forming some stable and shareable concept of what was unfolding in my mind. In the event, there was no coherent thought, just pure and terrible sensation. Only afterward did I wonder if this was what the mystics call the mysterium tremendum, the blinding unendurable mystery (whether of God or some other Ultimate or Absolute) before which humans tremble in awe. Aldous Huxley described it as the fear 'of being overwhelmed, of disintegrating under a pressure of reality greater than a mind, accustomed to living most of the time in a cosy world of symbols, could possibly bear.' Oh, to be back in the cosy world of symbols!

After the fact I kept returning to one of two metaphors, and while they inevitably deform the experience, as any words or metaphors or symbols must, they at least allow me to grasp hold of a shadow of it and, perhaps, share it. The first is the image of being on the outside of a rocket after launch. I'm holding on with both hands, legs clenched around it, while the rapidly mounting g-forces clutch at my flesh, pulling my face down into a taut grimace, as the great cylinder rises through successive layers of clouds, exponentially gaining speed and altitude, the fuselage shuddering on the brink of self-destruction as it strains to break free from Earth's grip, while the friction it generates as it crashes through the thinning air issues in a deafening roar.

It was a little like that.

The other metaphor was the Big Bang, but the Big Bang run in reverse, from our familiar world all the way back to a point before there was anything, no time or space or matter, only the pure unbounded energy that was all there was then, before an imperfection, a ripple in its waveform, caused the universe of energy to fall into time, space, and matter. Rushing backward through 14 billion years, I watched the dimensions of reality collapse one by one until there was nothing left, not even being. Only the all-consuming roar.

It was just horrible.

But there's sort of a happy ending

Norman Swan: Sort of? Well, you're here.

Michael Pollan: The best thing about 5-MeO-DMT is it only lasts about eight minutes

Norman Swan: But the longest eight minutes of your life.

Michael Pollan: It was the longest eight minutes of my life, but suddenly and very quickly the world starts reconstituting. I suddenly can feel I have a body and there's a floor, there's matter and I can tell time is passing. And so all the coordinates of reality came back, and I had this incredible rush of gratitude. But it was a new kind of gratitude. It wasn't the gratitude most of us have felt, the gratitude of being alive, it was the gratitude that there is anything, because there could just as easily be nothing. We could be before the Big Bang. So that kind of fundamental gratitude was a new experience for me. So I won't say it made it worth it, but close.

Norman Swan: How did people around you respond, your wife, your son, the people who know you, how did they respond? Did they see anything new, were you nicer to live with?

Michael Pollan: My wife Judith was nervous about the whole thing, for a couple of reasons. I think the big one was we've been together a very long time, we met in college, and all the big experiences of our adult lives we've shared, you know, having a kid, moving here or there, work experiences. And here I was going to have a big experience potentially and she wasn't part of it. And so she felt like it was going to put a certain distance between us. And she also confessed to being worried that I'd change in some way. It didn't occur to her I may change for the better.

Norman Swan: And if I were to interview her today here?

Michael Pollan: Well, if you were she would tell you a few things because I have asked her, you know, so do you think this changed me and in what ways? And she felt that it did. She felt it made me more open and more patient than I was and somewhat less defensive, which has to do with the kind of getting a little perspective on your ego. I think the value of having temporary ego dissolution is that you realise you're not as identical to your ego as you previously thought and that it is a character in the drama of your inner life, but it's not the only one and you don't always have to listen to it, and it has these moves and tricks that you can see for what they are.

Norman Swan: But you did take psilocybin with her before you started all this.

Michael Pollan: Yes, we did, so she ended up taking part in one of my experiences, and then subsequently a couple of others. So she found it interesting and useful, only her mother kept appearing in all these trips and

Norman Swan: The Jewish mother gets everywhere, I can tell you.

Michael Pollan: The Jewish motherwell, it didn't happen to me but it happened to her and it wasn't always happy.

Norman Swan: It's one of the reasons I had stay off it I think.

Michael Pollan: But the other thing she said that I thought was really interesting and telling was she thought that Imy father died a year ago in January, and she thought that I handled that very differently than I would have before these experiences. And what she meant was that I was very present for the last 10 days of his life, I kind of moved into the apartment. He was 88 and he died of lung cancer. And I was just with him, like hours and hours and hours and wanted to be there and lying with him in the bed and talking to him and saying what needed to be said. I'm a busy person who could have concocted excuses not to be there all the time, but I wanted to be, and that presence, that openness to his death I think had to do with the fact that I'd been interviewing all these cancer patients and had gotten very comfortable talking about death with them. Although he never talked about dying at all, he processed it to the extent he did very internally. And so I think there have been changes. It's not a night and day thing but I do think there has been some changes.

Norman Swan: There's one thing I noticed in the book, you talk about having interviewed 15 guides to end up with five you say in the book, but you only describe four experiences. What's the one you didn't put in the book?

Michael Pollan: Let's see, well, I'm not sure your maths is right.

Norman Swan: I'm a doctor, I can only add up to four or five.

Michael Pollan: I had a guided LSD trip, I had a guided psylocibin than trip, I had two ayahuasca and fiveyes, there were two ayahuasca trips.

Norman Swan: Any difference between the drugs or are they all pretty much the same?

Michael Pollan: I think it they are more unlike than not. I mean, leaving aside 5-MeO-DMT, I think psilocybin and LSD in my experience, the main difference is LSD lasts longer.

Norman Swan: Why are the researchers focusing on psilocybin rather than LSD?

Michael Pollan: It's a good question. Two reasons, one political and one practical. The practical reason is an LSD trip can last 10 hours, and the researchers want to get home for dinner. It's very hard to fit in to the work day. You'd have two pay a lot of overtime and it would make the research very expensive. And the other is that it's so notorious

Norman Swan: So it's the one the moral panic was over.

Michael Pollan: The moral panic was around LSD, not psilocybin. And frankly, politicians don't know what psilocybin is, most of them, and so you're not going to have some know-nothing politician screaming about the government funding psilocybin research, although they're not. So I think it's safer politically.

Norman Swan: You're listening to RN's Health Report with me Norman Swan, and a special conversation with writer and journalist Michael Pollan on the new science of psychedelics.

So you had the '50s where you had people like Cary Grant taking this, you had a lot of research, 40,000 subjects. And then it starts to go south, and Timothy Leary is often blamed for this. Fairly?

Michael Pollan: Yes and no. He definitelyso he begins as a very serious researcher, he's hired by Harvard, he has a psychedelic experience on psilocybin the summer before he goes to start at Harvard. He said he learned more about the human mind in four hours by the pool in the Cuernavaca then he had in 15 years of being a psychologist. And so he starts this project, but he very quickly gets bored with science and he starts turning on poets and musicians. His idea of research was to have a lot of people over to his house and give them all psilocybin. And the papers were like 'Psilocybin in a Naturalistic Setting'. He transcended science instead of his ego.

And so he began, when he got firedhe got fired from Harvard for his partner, Richard Alpert, who became Ram Dass, was giving the drugs to undergraduates. They were only allowed to give it to graduate students, so they had violated their relationship with Harvard. And after he is fired he becomes an evangelist. This is an occupational hazard. I mean, people get involved with LSD and they think it really can solve the world's problems. And I get that kind of thinking. There is a certain logic to it. But we don't have a model for administering a drug to a whole culture except for fluoride, and it's not like fluoride. So he starts proselytising. And the researchers think he's screwing it up for everybody and they try to stop him.

Norman Swan: Because it's still legal at this point.

Michael Pollan: It's still legal at this point, it's legal up until '66 and it's not really nationally illegal until 1970. But it becomesit's taken up by the counterculture. President Nixon thinks it's fuelling the reluctance of American boys to go to Vietnam, which may have been true. It did helpit wasn't the only factor creating the counterculture but it certainly gave it a lot of its character. It was an unprecedented moment, if you think about it, where since this was a new drug, the young were having a rite of passage, the acid trip, that their elders did not understand and found really frightening and scary. Normally rites of passage in a culture are designed to knit the culture together. So you have the vision quest and the Native Americans or the bar mitzvah for Jews, it's a trial set up by the adults and the adolescents do certain things and cross the river and join the adult community. Here you had this weird rite of passage that the kids had organised themselves essentially

Norman Swan: The acid test.

Michael Pollan: Acid tests. And it was landing them in a country of the mind that adults didn't understand, and it was frightening to the government. So there was a backlash. The media turned against it, the government turned against it, and pretty soon the researchers were out of business.

Norman Swan: So we're into the second wave, you've been asked this question before, could another Leary come along and spoil it now?

Michael Pollan: That's a good question. I think everybody is so mindful of that example, every researcher I talk to alludes to the example of Leary and they are being very careful not to over-hype what they've got.

Norman Swan: They've got a whole group of people who believe this is for the betterment of the well, to use the words that you use

Michael Pollan: Yes, and there are researchers who will say that off the record. It's very hard to get them to say that on the record, that this is not only useful for people who are sick, the kinds of people who are being treated for addiction and depression, but that it has potential to treat all of us. I wouldn't say they are all off the record, some of them are on the record but very careful about saying that. And they are right.

Norman Swan: These drugs rely on the testimonies of individuals. There's no randomised placebo-controlled trial here. We've tried but essentially it reliesit's like studying pain, you've just got to believe somebody when they say I am scoring 10 of pain.

Michael Pollan: Right, the phenomenologywhat else are you going to go on? You're talking about mental experience, yes.

Norman Swan: Will there ever be the scientific methodology to allow the regulators to say, 'yes, we will allow psilocybin on the market'?

Michael Pollan: Oh yes, and we are not very far from that, believe it or not. So there have been placebo-controlled randomised trials. It's very hard to do a placebo for a psychedelic. You can imagine. And they tried different things. They give people niacin, which gives you a tingling sensation, or methylphenidate, Ritalin, but peopleyou can fool them sometimes if you have a naivesomeone who has never used psychedelics, but basically it's a problem. Nevertheless, they see dramatic differences in the two groups. And on the cancer anxiety studies they got a very strong signal, stronger than we have seen in any other psychiatric intervention, by the way.

Norman Swan: And where do you sit on the decriminalisation, legalisation?

Michael Pollan: So let me just go a little further with this though about satisfying the FDA. The FDA is the Food and Drug Administration in the United States, or the EMA in Europe. They've set out the benchmarks they need to see, and if they can see essentially if it performs better than placebo or better than a current SSRI in depression, they will approve it. We don't know the brain mechanisms of lots of psychiatric drugs. We still don't know how SSRIs work. So they are not waiting for that kind of information, although it would be very interesting to get it, and there are people working on it.

Norman Swan: Getting to the end of it, you quote William James a lot, the Harvard physician and psychologist who wrote about the religious experience, and he talked about mind cures, interestingly. Is the religious experience just a physiological phenomenon?

Michael Pollan: Well, it's a very good question. We are learning the neural correlates of spiritual experience. The fact that you can use a chemical to induce or occasion a mystical experience is quite a remarkable finding. What does that tell us? I mean, it may be that there is a physiological basis for religious experience. And some people think that diminishes it, to have a spiritual experience caused by a molecule, but that's an assumption worth examining. It seems to me it's kind of more mystical and wonderful that a mushroom that grows in the world that you take into your body can give you a religious experience. That doesn't diminish this at all.

We tend to assumethere's a whole lot of interesting assumptions about human nature that happen, that it's cheating to use a chemical, for example, to have a spiritual experience, that's a very common belief. And maybeI mean, I'm kind of agnostic on it, you know, it's that idea that if you climb to the top of the mountain, you have earned it in a way that if you take a helicopter, you haven't, yet you have the same view. And is it just our puritan nature that says, no, you've got to work for it for it to mean anything? I mean, all mental experiences are mediated by chemicals, so why the fact that it comes from outside you is cheating rather than it coming from inside? I mean, I just think we need to have an open mind about all this. I don't know the answer.

Norman Swan: And your advice is to take a guide and put on the eye mask and put on the headphones and listen to music?

Michael Pollan: Well, I don't want to advise anybody to do this unless they really feel motivated to do it, but if they are going to do it I think you mitigate a lot of the risk by having a guide. You have the potential of having a much deeper and thorough experience because of the environment that an experienced guide creates. A guide can be just someone who has a lot more experience than you do who is not going to be taking the drug with you. But I think there are enormous advantages, I found, to working with a guide. I also had a very good experience without one, but at a high dose, don't travel solo, I really think that's risky.

Norman Swan: Please join me in thanking the fabulous Michael Pollan.

Michael Pollan: Thank you.

Norman Swan: Michael Pollan. And his book is called How to Change your Mind: The new science of psychedelics. That conversation was recorded at the Sydney Opera House in July.

But before you go I want to recommend another show from the ABC science unit which many of you would be already familiar with, All in the Mind with Lynne Malcolm has done a series of programs looking at this second wave of psychedelic research for mental health issues. Here's a snippet:

David Erritzoe: The experience is so odd and strange and sort of mystical, so it's more about actually encouraging and supporting them in going into that experience and let the drug experience guide them through it. Our role and interaction during the actual trip is for some of the participants quite minimal. If people found it really challenging and really felt like sharing some of it we let that happen as well, but we encourage people to go inside.

Lynne Malcolm: Is the idea that you are hoping that they get some sort of personal insight that they didn't have before that might help them with their depression?

David Erritzoe: Yes, and that goes hand in hand with what we have been seeing during the acute state with the psychedelic in healthy people, what happens in the brain, that the networks of the brain, the functional networks that we can measure with MRI, they seem to fuse into each other. So, suddenly a lot of functional connections of brain areas and brain networks, they are broken down, so suddenly other perspectives are possible, and that is some of what people are experiencing, that they get a new angle, a new insight, new meanings and new understandings and a sense of coming to terms with some things. People often feel some sort of reconnection, that people can have felt estranged in their depression from their own emotions, from other people around them, from the world in general, even from nature, and those connections seem to be re-strengthened by the experience.

Lynne Malcolm: The results from this pilot study were quite positive.

David Erritzoe: We saw that people's depression scores significantly dropped, in particular after one week, that was the first proper measure. And then the depression score stayed low overall, almost half, I think nine out of the 20, they were in remission after five weeks, and six of these had not relapsed, even after six months of follow-up. In that sense quite impressive results, it really had a significantly positive impact on most of the participants, even some people found it really, really challenging, it helped their depression, it helped their suicidality, their anhedonia, this sense of not being able to feel anything, which is classic for depression, anxiety dropped in parallel. So very promising results. I would probably use the word 'promising' because remember it's a small trial, it's an open-label trial.

Norman Swan: And we've posted links to these All in the Mind episodes on our website. I'm Norman Swan, this has been the Health Report, I'll see you next week.

Read more here:

Anxiety, depression and the new science of psychedelics part two - ABC News

Keeno Ahmed-Jones: Getting out of the psychedelic closet – Straight.com

By Keeno Ahmed-Jones

It was an early Sunday afternoon, and a scrum of more than 100 people had squeezed into the second-floor lounge of the Cannabis Culture head shop in Vancouver, B.C. This was not your prototypical stoner crowd: mostly women, they cut a wide demographic swath: college students, hipsters with bespoke tattoos, and a large contingent of grey-haired retirees wearing artfully tied scarves. The kind of folks you might see at a Green Party meeting, or a downtown Starbucks.

The event, a psychedelic symposium and fundraiser for Cosmic Sister, an ecofeminist collective, was running behind schedule. Celina Archambault, a petite blond with a distance runners spry build and the main organizer, was jockeying to find seats for people who had spilled over into the next roomone of the stores retail areas, anchored by a glass case brimming with a stoners delight of mass-market candy, rolling papers, and vape pens.

If you are wondering what a psychedelic symposium is, youre not alone. With the recent legalization of cannabis in Canada and the decriminalization of psychedelic drugs gaining ground in the U.S. and Canada, so are the people curious about magic mushrooms, ayahuasca, MDMA, and other mind-altering compounds for enlightenment and healing. The event at Cannabis Culture was part community gathering and part educational forum, featuring women directly involved in the world of plant medicine.

While the psychedelic renaissance seems to be heading mainstreamthrough multiple TED Talks, HR-approved microdosing in Silicon Valley offices, and author Michael Pollan tripping his way to the New York Times bestseller listthe effort to get psychedelics recognized for their therapeutic benefits has been waged for decades. Canada sits at a critical nexus: the first major country to pass progressive drug policy (cannabis) and being at the forefront of groundbreaking hallucinogenic research.

But lets not forget history. In the 1950s, government-sanctioned psychedelic studies were being conducted around the world; LSD, psilocybin, and MDMA were found to have beneficial effects for people suffering from a variety of conditions, including anxiety, PTSD, and addiction. A decade later and a series of cascading eventsTimothy Learys fervent LSD crusade, the 60s counterculture, and President Nixons all-out antidrug offensiveresulted in overzealous drug regulation and an unceremonious end for grant-funding, effectively slamming the door on psychedelic research for half a century. And yet, all the while, a steady stream of scientists, therapists, and healers have been working with these substances underground to help people who are suffering.

I recently moved to Vancouver, B.C., after living in New York City for more than 20 years. Canadawith its socialized health care, pragmatic gun laws, and affordable college tuitionseemed a viable antidote to the Sisyphean labours of big-city life. A few months before leaving New York, I attended a private salon at a sprawling Soho loft, where Rodrigo Nio, an accomplished real-estate developer and economist, spoke about his Stage 3 melanoma diagnosis in 2011 at the age of 41. Suffering from a crippling fear of death, he flew to Peru and did ayahuasca under a shamans guidance. Nios experience was transformativehis dread evaporated, and the potential of life, however fragile, bloomed in its place. Nio eventually beat cancer and is healthy and thriving today.

Ever since that night, I found myself asking: could these substances help me with my anxiety, insomnia, and past trauma? I had spent the better part of my life in New York paying handsomely for the privilege to contribute toward the vacation-home slush funds of three psychotherapists. Despite their Ivy League credentials and thriving practices, and regardless of the neuro-linguistic programming (NLP), eye-movement desensitization reprocessing (EMDR), and Big Pharma medications (which went mostly untouched), I never felt like Id been cured or harnessed a deeper understanding of my own psyche. If any viable mental health alternatives existed out there, any at all, didnt I owe it to myself to find out?

With everyone finally situated, Ms. Archambault stood at the microphone and welcomed everyone. She spoke about the corporatization of cannabis and the domination of plant medicine in the 21st century by white men, in spite of its Indigenous roots, how colonialism and the War on Drugs had demonized these powerful agents of healing and pushed them underground. It was time, she said, for women to shake off multiple generations of repression and educate and empower ourselves, to reclaim the spaces we had been pushed out of as healers, cultivators, and wisdom carriers.

A procession of women from diverse backgrounds took the microphone during the next two hours. There was an elderly midwife and medicine woman who talked about salvia divinorum, asacred hallucinogen of the Mazatec Indians that gained YouTube notoriety when legions of bored teens (including Miley Cyrus) posted their chaotic 10-minute trips to oblivion and back, eventually causing its reclassification as a controlled substance in the U.S. and Canada. She scoffed at the hyperbolic tabloid headlines and told the audience: If you take the plant to its highest elevation, you can actually meditate on it.

Eight more women spoke, including: the young owner of the only First Nations-run cannabis shop in Vancouver (cleverly named the 420 Stalk Market), a psychotherapist with the MDMA Phase III Research Study who provided tips on how to approach a psychedelic journey, an Indigenous activist and mother working to heal her reserve from intergenerational trauma, an organic cannabis farmer, and a chef specializing in the preparation of special meals eaten in the days leading up to a psychedelic journey.

But the most resonant speaker was Anne-Marie Armour, a social worker who has spent several years working in Vancouvers Downtown Eastside, ground zero of Canadas opioid epidemic. Without mincing words, she told the crowd that the high cost of psychedelic-assisted therapy meant it was simply out of reach for the poor and marginalized. That practitioners using plant medicine with their clients do so at the risk of losing their licences. And psychedelic researchers, advocates, policymakers, and the community at large need to acknowledge its Indigenous origins and ensure that Native healers are represented where policy and practice is concerned. Plant medicine, she said, firmly, needs to get out of the psychedelic closet.

After the speakers had finished and most of the attendees had filtered out, I found Armour and thanked her. I shared my struggle to find a local, affordable nontraditional therapist (the last one I had been referred to charged $450 for the initial consultation alone). I know how you feel, Armour said, nodding knowingly.

I stayed after and mingled for a bit. A woman suffering from epilepsy told me that microdosing with mushrooms had remade her from a shut-in fearing her next seizure to having a functional life where she could hold down a job. A mother said she was there for her son, a 20-something heroin addict who had overdosed half a dozen times and been in rehab twice. She had seen the new documentary Dosedwhere ibogaine therapy was used to end a heroin addicts opioid dependenceand wanted to learn more.

Walking out under the intransigent Vancouver sun, I tried to process everything Id heard in the past few hours. I felt exhilarated but also a bit angry that most people in the world were stillthrough no fault of their ownin the dark when it came to the truth about psychedelics.

But above all, I was heartened to know that there were people in Canada and beyond working in the shadows and the light of day to make sure that the door to the psychedelic closet was reopenedand that this time around, it would stay that way.

Read this article:

Keeno Ahmed-Jones: Getting out of the psychedelic closet - Straight.com

Call for patients to take part in anorexia psilocybin treatment study – Health Europa

One condition that psilocybin has been shown to hold potential as therapy treatment for is eating disorders, and a psychedelic research centre is calling for patients to take part in an anorexia psilocybin treatment study.

Psilocybin is a naturally occurring psychoactive substance found in certain species of mushrooms and research into the chemical has been limited due to its scheduling as an illegal drug in many countries across the world.

Johns Hopkins University recently secured funding of $17m (~15.39m) to start the Center for Psychedelic and Consciousness Research at Johns Hopkins Medicine, making it the largest research centre of its kind in the world. The centre will be carrying out research in the hope of creating precision medicine treatments tailored to individual patients specific needs.

Psychedelics are a class of drugs that produce unique and profound changes of consciousness over the course of several hours. Much of the early work at Johns Hopkins has focussed on psilocybin, the chemical found in so-called magic mushrooms.

A study that will be carried out at the centre will be looking at the psychological effects of psilocybin, including whether or not it can help with anorexia.

Anorexia kills more people than any other mental health condition and there are many related medical and mental complications that come with it including thoughts of suicide.

Paul B. Rothman,dean of the medical faculty at the Johns Hopkins University School of Medicine and CEO of Johns Hopkins Medicine, said: Johns Hopkins is deeply committed to exploring innovative treatments for our patients.

Our scientists have shown that psychedelics have real potential as medicine, and this new centre will help us explore that potential.

The researchers at Johns Hopkins University are now seeking individuals ages 18 65 with anorexia nervosa to participate.

The centre reassures that confidentiality will be maintained for all applicants and participants.

Click here to apply to participate in the anorexia study.

Roland Griffiths, the centres director and professor of behavioural biology in the Department of Psychiatry and Behavioural Sciences and the Department of Neuroscience at the Johns Hopkins University School of Medicine, said: The centres establishment reflects a new era of research in therapeutics and the mind through studying this unique and remarkable class of pharmacological compounds.

Read the original post:

Call for patients to take part in anorexia psilocybin treatment study - Health Europa

DOJ Awards ~$153 Million to Reduce Crime, Improve Public Safety in Georgia – All On Georgia

The Peach State has received a considerable amount of money from the federal government to combat crime and improve public safety.

Principal Deputy Associate Attorney General Claire Murray and Office of Justice Programs Principal Deputy Assistant Attorney General Katharine T. Sullivan joined Georgia First Lady Marty Kemp on Tuesday in announcing awards of almost $153 million to fight crime and improve community safety in Georgia.

Nearly $4.3 million will help law enforcement officials and victim service providers in the state investigate and prosecute human traffickers and aid human trafficking survivors. U.S. Attorney for the Northern District of Georgia Byung J. BJay Pak, U.S. Attorney for the Middle District of Georgia Charlie Peeler and Georgia Attorney General Chris Carr also participated in the announcement.

Human trafficking is a cruel and barbaric practice that calls to mind the darkest moments of our history, and sadly it has left its mark on the communities of Georgia, said Principal Deputy Associate Attorney General Murray. Under the direction of Attorney General Barr, the Department of Justice is putting the full weight of its resources behind the brave men and women of the state who are fighting trafficking perpetrators and bringing relief to victims. We commend these courageous and compassionate professionals and are proud to lend them our full support.

Human trafficking is an obscene violation of human rights and human dignity, affecting millions of people worldwide, countless victims in this country and hundreds if not thousands of men, women and children right here in Georgia, said Principal Deputy Assistant Attorney General Sullivan. We are so grateful to the law enforcement officers who pursue these vicious criminals and to the dedicated service providers who work around the clock to get survivors the help they so desperately need and deserve.

Department officials and First Lady Kemp made the announcement at a press event alongside law enforcement officials, anti-trafficking advocates and members of the Georgia Criminal Justice Coordinating Council. Georgias leaders have concentrated the states resources on fighting human trafficking, establishing a Human Trafficking Prosecution Unit in the Georgia Department of Law. First Lady Kemp co-chairs the Georgians for Refuge, Action, Compassion and Education, or GRACE, Commission, a task force of public officials, law enforcement and health care professionals, for-profit and non-profit organizations and subject matter experts dedicated to combating human trafficking in Georgia.

Many trafficking victims in Georgia are teenagers who are sexually exploited. Of the 375 cases reported from the state to the National Human Trafficking Hotline last year, most involved sex trafficking and almost a quarter involved a minor. During an FBI-led, month-long, nationwide operation focused on recovering child victims of sex trafficking, known as Operation Independence Day, the FBI, in cooperation with 400 law enforcement agencies, identified and/or recovered more than 100 child victims of sex trafficking, including seven in Georgia. Law enforcement officials also arrested 67 suspected traffickers. Grantee organizations that received previous Justice Department funding served 140 human trafficking clients in 2018.

The awards today support a range of activities designed to bring sex and labor traffickers to justice and provide critical services to victims. A grant to the Georgia Criminal Justice Coordinating Council will fund a multidisciplinary task force composed of law enforcement agencies, including the Georgia Bureau of Investigation, and several victim service organizations. Funds will also support direct victim services provided under the auspices of the Georgia Coalition to Combat Human Trafficking. Other awards will help ensure that children and minors who are victimized receive counseling, case management and other critical services. Georgia Care Connection Office, Inc.; Wellspring Living, Inc.; Tapestri, Inc.; and the Georgia Center for Child Advocacy are among the grant recipients.

Human and sex trafficking are not victimless crimes. These grants will go a long way in not just furthering our prosecutorial efforts for these terrible crimes, but also in providing much needed victim-centered services. Our office continues to be fully committed to eradicating human trafficking within the Northern District of Georgia, said Byung J. BJay Pak, U.S. Attorney for the Northern District of Georgia.

In Georgia, the fight against human trafficking is a coordinated effort of federal, state and local law enforcement and prosecuting agencies working together to identify, arrest and prosecute those who choose to engage in this horrific industry, said U.S. Attorney for the Middle District Charlie Peeler. In the Middle District, we aggressively investigate and prosecute cases where offenders prey on vulnerable citizens, taking advantage of their age, their desire for love and affection, their financial status and their addictions. I am confident that these federal dollars will provide critical support to those who are dedicated to protecting victims and arresting perpetrators, which will lead to the end of human trafficking in our state.

Human trafficking is a pervasive, growing threat plaguing communities across our state and country, said First Lady Kemp. I applaud the federal, state and local partners who are committed to healing victims, seeking justice and holding bad actors accountable. By working together, we will end this criminal enterprise once and for all.

We thank the Department of Justice for making it possible for us to continue and expand on our anti-trafficking efforts in Georgia, said Georgia Attorney General Chris Carr. The resources announced today, will help ensure more victims in Georgia get the support they need and help ensure that our law enforcement officials have every tool at their disposal to put buyers and traffickers behind bars where they belong.

The remainder of the states awards cover a wide range of criminal justice, juvenile justice and victim service activities. Grants will support school safety initiatives, law enforcement hiring, services for domestic violence and sexual assault victims, inmate reentry services, youth mentoring and efforts to combat online child exploitation and manage sex offenders. Awards were made by the three grant-making components of the Department of Justice OJP, the Office of Community Oriented Policing Services and the Office on Violence Against Women.

Continued here:

DOJ Awards ~$153 Million to Reduce Crime, Improve Public Safety in Georgia - All On Georgia

Solid Biosciences Stock Crashes Over Safety Concerns About Its Gene Therapy – Barron’s

Text size

Solid Biosciences showed signs Tuesday morning of facing serious setbacks for its Duchenne muscular dystrophy gene therapy, sending the biotechs shares down about 70% in early trading.

Solid (ticker: SLDB) said the Food and Drug Administration had put its Phase I/II study of its experimental gene therapy treatment for Duchenne muscular dystrophy on clinical hold after one of the six patients dosed with the treatment suffered acute kidney injury, among other serious side effects.

This is the second clinical hold placed on this study. In March 2018, the FDA held the study after a patient in the low-dose cohort was hospitalized.

We are encouraged that this patient is recovering, Solid Biosciences CEO Ilan Ganot said in a statement. We remain committed to bringing meaningful new therapies to the Duchenne community and continue to believe in the differentiated construct of SGT-001 and the potential benefits it may offer to patients.

Solid is one of a number of companies seeking to be the first to bring to market a gene therapy to cure Duchenne muscular dystrophy, a genetic disorder that produces muscle weakness and dramatically shortens the life expectancy of people who suffer from it. Wall Street has increasingly seen Sarepta Therapeutics (SRPT) as having the leading Duchenne muscular dystrophy gene therapy candidate, after Solid released disappointing data earlier this year.

Pfizer (PFE) is also developing a competing gene therapy.

Ganot founded the company after his son was diagnosed with the disease. Safety concerns have long dogged Solid. In January of 2018, gene therapy pioneer James Wilson resigned from the companys scientific advisory board, according to a company filing, over emerging concerns about the possible risks of high systemic dosing of AAV, the viral vector used to deliver the gene therapy.

In its Tuesday morning statement, Solid said three patients given a lower dose of the experimental gene therapy continue to do well, as do two of the three patients given a higher dose. But one of the patients who received the higher dose fell ill.

The third patient...dosed in late October, experienced a serious adverse event (SAE) deemed related to the study drug that was characterized by complement activation, thrombocytopenia [low blood platelet count], a decrease in red blood cell count, acute kidney injury, and cardio-pulmonary insufficiency, the company said.

In a note out Tuesday morning, SVB Leerink analyst Joseph P. Schwartz noted that the new adverse event resembles the one from March 2018.

The safety profile of SGT-001 will most likely be under increased scrutiny, Schwartz wrote.

Solid Biosciences stock was recently trading 68.6% lower at $3.45.

Write to Josh Nathan-Kazis at josh.nathan-kazis@barrons.com

Visit link:

Solid Biosciences Stock Crashes Over Safety Concerns About Its Gene Therapy - Barron's

Solid’s Duchenne gene therapy trial halted after patient suffers toxicity – STAT

The Food and Drug Administration has halted a clinical trial involving a Duchenne muscular dystrophy gene therapy from Solid Biosciences (SLDB) after a patient suffered serious kidney and blood-related injuries, the company said Tuesday.

This is the third time that the Cambridge, Mass.-based Solid has run into a serious safety problem with its gene therapy, called SGT-001. The FDA placed similar clinical holds on the same clinical trial after each prior incident, but later allowed the company to proceed with patient dosing.

SGT-001 uses an inactivated virus to deliver a miniaturized but functional version of the dystrophin gene to muscle cells. The gene therapy is designed to be a one-time and potentially curative treatment for all Duchenne patients, regardless of the mutation that causes their disease.

advertisement

Sarepta Therapeutics (SRPT) and Pfizer (PFE) are also developing their own gene therapies targeted at Duchenne.

Six patients have been dosed with SGT-001, starting with three at a lower dose; interim results in those patients were previously reported and found to be disappointing. Three more patients were then treated at a higher dose of SGT-001.

The sixth patient became ill soon after being treated in October, experiencing an over-activation of the immune system, an acute kidney injury, reductions in platelets and red blood cells, and cardio-pulmonary insufficiency, Solid said.

All of the toxicities were deemed related to SGT-001 by the patients treating doctor. The patient is being treated and is recovering, Solid said.

Solid reported the patients status to the FDA, which then placed the clinical trial on hold. In a statement, the company said it will work with the FDA in an effort to resolve the hold and determine next steps for the clinical trial.

Pfizers Duchenne gene therapy has also been tied to similar immune system over-activation and related kidney toxicity, although its clinical trial remains active.

Go here to read the rest:

Solid's Duchenne gene therapy trial halted after patient suffers toxicity - STAT

Gene Therapy in Neurology: 2019 Overview & Forecast Report – Yahoo Finance

Dublin, Nov. 12, 2019 (GLOBE NEWSWIRE) -- The "Gene Therapy in Neurology" report has been added to ResearchAndMarkets.com's offering.

Gene therapy is an evolving area in healthcare that promises to revolutionize the treatment landscapes across various therapy areas.

In this report, the focus will be on neurology indications. The report provides an analysis of the overall gene therapy pipeline that is being developed for various neurology indications with an emphasis on late-stage pipeline products. In addition to pipeline analysis, the report also focuses on trends observed in clinical trials in this area, unmet needs and challenges, as well as partnership strategies adopted by pharmaceutical companies to keep up with developments in the field of gene therapies.

Recently approved gene therapies for spinal muscular atrophy have reinvigorated the potential of such therapies to transform patient care. While various methodologies can be adopted in order to deliver therapeutic benefits of gene therapy including gene augmentation, gene suppression, and gene editing, an important component of gene therapy is whether to use viral or non-viral vectors in order to deliver such therapies to the point of care.

Ongoing collaborations between different industry players and a buildup of real-world evidence establishing safety and efficacy are expected to drive the growth of gene therapies for neurology indications. Of the 38 pipeline products that are currently in development, 45% are adeno-associated virus (AAV) based delivery platforms. Other types include Lentiviral, which accounts for 13%.

A majority of the current pipeline products are in Phase II development and the most common neurology indications - for which gene therapies are currently being evaluated - include Parkinson's disease, pain and amyotrophic lateral sclerosis. The dominance of viral vectors is expected to continue as such platforms account for the bulk of these pipeline products, with adeno-associated virus being the most common among the viral vectors.

In terms of completed, ongoing and planned clinical trials, academic institutes account for 21% of these trials, despite industry sponsors being most dominant. A deeper analysis of these clinical trials also suggest that across most indications, the average trial duration for a viral based product is longer compared to a non-viral based product such as oligonucleotides or plasmid DNA.

There are also challenges associated with the development of gene therapies, most prominent being their high price points. Key opinion leaders (KOLs) interviewed highlighted the need to create sustainable funding solutions so that such therapies become accessible to patients everywhere irrespective of where patients are located. In terms of unmet needs, KOLs highlighted the need for a favorable route of administration that is both sustainable in terms of usage of healthcare resources and favorable from a patient perspective.

While development of gene therapies are expected to pick up pace, the next wave of such therapies are expected to be ones that target diseases that are more frequent. While monogenic rare diseases are the obvious first-to-go choice for which gene therapies can be developed, targeting more frequent diseases will need a holistic approach in order to address a wider mechanism of action. If gene therapies for frequent diseases do become available, then that will result in a more pronounced effect on healthcare not only in terms of providing better treatment options for patients but also test the ability of healthcare organizations to adapt with high price points of these therapies.

Scope

Reasons to Buy

Key Topics Covered

1 Preface

2 Executive Summary2.1 Key Findings2.2 KOL Insights on Competitive Landscape for Gene Therapy for Neurology Indications

3 Overview - Gene Therapy in Neurology3.1 Objectives of Gene Therapy 3.2 Gene Therapy Versus Conventional Therapies3.3 Optimization of Gene Expression3.4 Gene Transfer Methods and Vectors Used for Gene Therapy3.5 Classifications of Gene Therapy3.6 Sources

4 Gene Therapy in the 8MM4.1 Global Regulatory Agencies' Definitions of Gene Therapy4.2 Gene Therapy in the US 4.3 Gene Therapy in the EU4.4 Gene Therapy in Japan4.5 Gene Therapy in China4.6 Currently Marketed Gene Therapies in Neurology4.7 Sources

5 Pipeline Assessment in the 8MM 5.1 Pipeline Overview 5.2 Pipeline Products - Phase III5.3 Pipeline Products - Phase II5.4 Orchard Therapeutics' OTL-200 5.5 Biogen's Tofersen Sodium5.6 Roche's RG-5.7 Sylentis' Tivanisiran5.8 ViroMed's Donaperminogene Seltoplasmid5.9 Sources

6 Clinical Trials Mapping and Design6.1 Clinical Trial Mapping for all Pipeline Products by Phase, by Sponsor, and by Location6.2 Clinical Trial Mapping for all Pipeline Products by Status and by Indication6.3 Clinical Trial Mapping by Phase and Indication for Phase III Therapies6.4 Clinical Trial Mapping by Phase for Phase II Therapies6.5 Clinical Trial Duration by Indication for Phase III Therapies (By Types of Molecules)6.6 Clinical Trial Duration by Indication for Phase II Therapies (By Types of Molecules)6.7 Ongoing Clinical Development of Phase III Gene Therapies

7 Unmet Needs, Barriers, and Key Company Strategies 7.1 Unmet Needs Within Gene Therapy for CNS Indications7.2 Challenges and Other Factors to Consider During Different Stages of Product Development7.3 Key Company Strategies: Acquisitions7.4 Key Company Strategies: Strategic Partnerships7.5 Sources

8 Payer Perspective on Gene Therapies in Neurology8.1 Current Neurology Space8.2 Challenges Associated with Reimbursement of Novel Gene Therapies8.3 Cost of Gene Therapies8.4 Strategies to Tackle the Cost of Gene Therapies8.5 Innovative Reimbursement Models and Clinical Comparators

9 Market Outlook9.1 Phase III Gene Therapy Pipeline for Neurology9.2 Key Launch Dates for Phase III Gene Therapy Pipeline Products

Companies Mentioned

Story continues

For more information about this report visit https://www.researchandmarkets.com/r/7amvqe

Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research.

CONTACT: ResearchAndMarkets.comLaura Wood, Senior Press Managerpress@researchandmarkets.comFor E.S.T Office Hours Call 1-917-300-0470For U.S./CAN Toll Free Call 1-800-526-8630For GMT Office Hours Call +353-1-416-8900

Visit link:

Gene Therapy in Neurology: 2019 Overview & Forecast Report - Yahoo Finance

How Gene Therapy Is Evolving to Tackle Complex… – Labiotech.eu

Gene therapy has traditionally been applied to well-understood diseases where a single genetic mutation was to blame. A new generation of technology is expanding the potential of gene therapy to treat conditions that were previously unreachable.

Since the first gene therapy clinical trials in the 1990s, the technology has made its way into the market for conditions ranging from blindness to cancer.

Gene therapy has the potential to fix any genetic mutation causing disease by inserting a new copy of the faulty gene. However, its reach has historically been limited.

Weve been constrained with the things we can do with gene therapy, said Dmitry Kuzmin, Managing Partner at 4BIO Capital, a London-based VC that specifically invests in advanced therapies. If you look across the successes in gene therapy in the last five years, most of these were in diseases that are pretty straightforward from the engineering perspective.

Technical limitations have meant that gene therapy has been restricted to rare diseases caused by a single genetic mutation, as well as to certain areas of the body, such as the eye and the liver.

According to Kuzmin, there have been so far three generations of gene therapy technology. Generation one would be classic single-gene replacement, such as Luxturna, a gene therapy to fix a specific genetic mutation causing blindness. Generation two would consist of using gene therapy to introduce new functions. An example is Kymriah, where immune cells are equipped with a molecule that helps them hunt down cancer cells.

The third generation is the one that could hold the key to unlocking the full potential of gene therapy. It englobes several technologies that can be used to introduce a new drug target into the patient, making it possible to turn the therapy on and off as well as to tune its intensity.

As the first two generations get optimized and the third generation enters the clinic, we are now expanding our reach into areas that have been previously rather inaccessible, Kuzmin told me. One of them is the brain.

Treating the brain has long been a huge challenge for medicine. Take epilepsy, for example.

Epilepsy affects 1% of the whole population and about 30% of people with seizures of epilepsy continue to have seizures despite medication, said Dimitry Kullmann, Professor at University College London. Theres a paradox. We have a good understanding of the mechanisms behind epilepsy, but were unable to suppress seizures in a significant proportion of people with epilepsy.

The reason is that the molecules that we use for drugs dont target the epileptic zone of the brain; they bathe the entire body with medication, Kullmann told me. These drugs dont differentiate between neurons and synapses that derive the seizures, and those parts of the brain that are responsible for memory, sensory functions, motor functions and balance.

Gene therapy could provide a solution for this problem. Kullmanns group has been researching this approach for years and is now getting ready to start the first clinical trial in humans within a year.

A gene therapy can be directly injected in the area of the brain causing seizures. Furthermore, using DNA sequences called promoters, it is possible to restrict the effect of gene therapy to specific neurons within that area. In the case of epilepsy, gene therapy can be used to decrease the activity of only excitatory neurons, which cause epileptic seizures when they are overactive.

Another approach that Kullmans group is testing is chemogenetics. The idea here is to use gene therapy to put a specific receptor into the neurons, explained Kullmann. This receptor is designed to respond to a drug that, when given to the patient, decreases the activity of the neuron to suppress seizures.

The advantage is that you can switch on and off the therapeutic effect on demand by just giving, or not giving the drug, Kullmann said. This approach can thus make gene therapy more precise, being able to tune it to the specific needs of each patient. In addition, it reduces the big challenge of getting the dose right in a one-off treatment.

Ultimately, this technology could allow scientists to target a wide range of conditions that come under the umbrella of epilepsy, rather than just a specific form of the condition caused by a genetic mutation.

The approach could be extended to other conditions involving the brain, such as Parkinsons, ALS and pain. However, this kind of research is still at an early stage and it will take a while until its potential is proven in humans.

Blindness has been a major target of gene therapy because of the fact that the eye is an ideal target for this technology. The activity of the immune system is suppressed in the eye, minimizing the chances of rejection. In addition, unlike other cells in the body, those involved in vision are not renewed over time, being able to retain the injected DNA for years.

However, there are hundreds of genetic mutations that can cause blindness. With the classical gene therapy approach, a different therapy would have to be developed from scratch for each mutation. While some companies are doing just this for the most common mutations causing blindness, many other less frequent mutations are being left behind.

Others are turning to new generations of gene therapy technology. We figured out that it would be very, very difficult to use the classical gene therapy approach in each individual mutation, said Bernard Gilly, CEO of GenSight, a Parisian biotech developing gene therapies for blindness.

While the companys leading programs follow this classical approach, the company has also started clinical trials using a technology called optogenetics. Following a similar principle to gene therapy, optogenetics consists of introducing a protein that reacts to light into a cell.

GenSight is using optogenetics to develop a single therapy for the treatment of retinitis pigmentosa. This genetic condition can be caused by mutations in any of over 200 genes and results in progressive vision loss in children due to the degeneration of photoreceptor cells that perceive light and send signals to the brain.

With optogenetics, it would be possible to transfer the lost photoreceptor function to the cells in the retina that are responsible for relaying visual information to the brain. Using specialized goggles, the images captured by a camera are transformed into light patterns that stimulate these cells in the precise way needed for the brain to form images.

The company is currently testing this approach in clinical trials. We believe that this approach will allow us to restore vision in those patients who became blind because of retinitis pigmentosa, Gilly told me.

Optogenetics would not work a miracle, but it might be able to give people back the ability to navigate an unknown environment with a certain level of autonomy. Recognizing faces is a more challenging goal; although reading is not yet on the horizon, according to Gilly.

Still, the potential of optogenetics to address multiple genetic mutations with a single treatment might be revolutionary. As long as the neurons responsible for sending light signals to the brain are intact, this approach could be extended to other forms of blindness. In addition, conditions affecting the brain such as epilepsy, Parkinsons or ALS could be treated with this approach by introducing an implant to shine light on the target neurons.

However, approaches applying optogenetics to the brain are still further down the line. While optogenetics technology has been around for over 20 years, its application in humans is still very limited and in the early stages of research.

Chemogenetics and optogenetics are just two out of a wave of new technologies addressing the historical limitations of gene therapy. Other approaches are in development, such as using thermogenetics, which consists of introducing proteins that are activated by the heat created by infrared light.

With a growing range of tools available, it is becoming easier than ever for scientists to develop gene therapies that can address the specific challenges of different conditions affecting areas of the body. Traditionally, locations such as the heart, the lungs or the pancreas have been particularly difficult to target with gene therapy. That might soon stop being the case.

As we go forward, were interested in taking gene therapy out of this little box and trying to use all the knowledge we have to benefit patients in larger indications, said Kuzmin.

As gene therapy expands into more mainstream conditions, it could take precision medicine to a whole new level and help address the big variability that is often seen across patients with the same diagnosis.

See the original post:

How Gene Therapy Is Evolving to Tackle Complex... - Labiotech.eu

Lonza taps Cryoport to bolster cell and gene therapy delivery – BioPharma Dive

Dive Brief:

Lonza is betting big on the future of gene and cell therapy and trying to offer customers an end-to-end solution to meet the complex challenges that come with the field.

Every stage of cell therapy, from patient apheresis through transport, genetic engineering and reinfusion comes with critical requirements for temperature control, speed and chain of identity.

Cryoport operates in more than 100 countries and supports more than 413 clinical trials. Notably, the company also supports three approved therapies: Gilead's Yescarta(axicabtagene ciloleucel), Novartis' Kymriah(tisagenlecleucel) and Bluebird bio's Zynteglo.

Demand for specialized manufacturing and distribution services is growing as researchers figure out new ways to manipulate cells so they can fight cancer and other diseases, Cryoport CEO Jerrell Shelton said in the statement.Cryoport's temperature-controlled supply chain systems fit well with Lonza's manufacturing services, he added.

For Lonza, cell and gene therapies are a new focus, part of a broader turn to the pharmaceutical side of the contract manufacturer's business.

In April 2018, the Swiss CDMO opened the doors to a 300,000 square-foot plant in Texas dedicated to producing the complex treatments.

CEO Marc Funk told BioPharma Dive in an interview earlier this year that Lonza has now worked with over 45 customers seeking supply of viral vectors, which are used to deliver gene therapies.

Read the original:

Lonza taps Cryoport to bolster cell and gene therapy delivery - BioPharma Dive

Pfizer’s ‘brainstorming’ payment deals as gene therapies advance, exec tells Bloomberg – FiercePharma

Gene therapies offer a "world of wonders" for patients, but with some 10,000 of the pricey therapies in development, pharma companies and payers need to get outcomes-based payments nailed down, a top Pfizer exec told Bloomberg.

What's more, Pfizer biopharma president Angela HwangtoldBloomberg's Cynthia Koons, gene therapies present some unique scientific and manufacturing challenges.

Gene therapies currently target monogenic diseases, or diseases that are characterized by a single genetic mutation, Hwang said. There are about 3,000 such disorders, and they're all considered rare diseases. Pfizer itself has three gene therapies in development for hemophilia A, hemophilia B and Duchenne muscular dystrophy.

OTC Innovation to Avoid Stagnation: Survey Insights, Expert Advice, and Latest Technologies to Boost Your Products Performance

Join us for a complimentary webinar on November 13 at 11am ET / 8am PT. Listen to industry experts as they analyze the critical role of innovation in OTC products, and strategies for achieving it.

Overall, there are 10,000 gene therapy programs in development,Hwang said. If 10% of them end up working,you start to see that potentially gene therapy can become a mainstaytherapyin how we manage diseases," she said in the Bloomberg interview.

That necessitates the key question about payment.Currently, payment systems are centered on paying for individual drug doses. Hwang said the industry needs to get outcomes-based payments worked out, adding that the process could become easier as science advances and data collection improves.

RELATED:Pfizer amps up gene therapy manufacturing with another North Carolina facility

Looking ahead, new gene therapy launches will necessarily drive us to come up with different solutions other than the ones we have today, Hwang said in the interview, referencingsubscription-based payments as one option.Her company is already brainstorming with payers, she added.

There are just two launched U.S. gene therapiesNovartis'Zolgensmaand Spark Therapeutics' Luxturna. Roche is in the process of acquiring Spark, but the buyout has been held up by antitrust regulators.

With already approved gene therapies, the market is adapting. Novartis has offered to allow payers to fund its spinal muscular atrophy gene therapyZolgensmawhich costs $2.125 millionover a period of five years. Thedrugmakerhas also proposed pay-for-performance deals.

Bluebird bio recently won European approval for itsbeta-thalassaemiagene therapyZyntegloand is allowing payers to pay for the drug over several yearsas long asthe med continues to workfor patients.

For its part, Pfizer is buildinga gene therapy manufacturing plant in North Carolina to manufacture clinical trial supplies and potential commercial products following approvals.

Read more:

Pfizer's 'brainstorming' payment deals as gene therapies advance, exec tells Bloomberg - FiercePharma

Next generation cell and gene therapies: fine tuning the promise – Business Weekly

On 19 November, the UK BioBeat19 summit goes to Stevenage to discuss the potential of cell and gene therapy and how to accelerate these transformational medicines.

Victoria Higgins of GSK and Miranda Weston-Smith from BioBeat spoke to two panellists who gave a sneak peek of their remarks and agree wholeheartedly that the discovery side and clinical side work best when they are teamed up.

Sophie Papa, an oncologist at Guys Cancer at Guys and St Thomas NHS Trust, and Aisha Hasan, a clinical development lead at GSK, both recognise the big challenge ahead for cell therapy researchers: to dial up efficacy and dial down toxicity.

Cell and gene therapies, with their remarkable potential to transform medicine, have seen some important but hard-won milestones: it took 20 years of combined academic and industry research to deliver the first gene therapy approval in 2016 and today there are two CAR-Ts approved for haematological malignancies.

Whilst CAR-Ts recognise proteins expressed on the tumour cell surface, making them ideal for targeting blood cancers, more complicated but with greater potential to address solid tumours are the gene modified TCR-T technologies.

These harness the power of T cells to specifically target and destroy tumours even on the inside of cells. TCR-Ts come with an additional level of complexity, but potentially open the door to a range of untreatable cancer types.

Looking at the TCR opportunity is where Sophie Papa sees the inherent trade-off between risk and benefit as an academic clinician whos now evaluating modified T-cell based therapies in clinical trials.

Sophie urges her peers to take courage. It is important to be brave and tolerant of certain toxicities. Academic clinicians and drug researchers need to work closely together to engage the regulators in early discussion, so that we can move cell therapies earlier in treatment schedules as soon as feasible.

Timing is critical to enable patients to be treated when they are physically fit so they can better tolerate these complex and potentially toxic treatments.

From her perspective, this is not an either/or, but an area where discussion and open dialogue will allow us to make the most of the opportunity. By allowing clinical academics to play a lead role in developing guidelines to manage patient safety, we can address legitimate concerns but not let them stand in the way of clinical development, she says.

Aisha brings the perspective of drug discovery and development and starts by asking what is in the realm of the possible from a design perspective.

She says: A superior T-cell therapy will require engineering approaches that enhance efficacy on one-end while also incorporating switches to minimise toxicity.

For example, in a counter-intuitive way, a T-cell with high-killing capacity actually can create dangerous levels of inflammation in the body, due to the rapid death of cancer cells. But the beauty of drug design opens up options:By building a switch within the engineered T-cells, researchers can inactivate the T-cells and prevent harm to the patient, says Aisha.

But this creative problem solving requires open dialogue between clinicians and pharma. Aisha says: The more we talk about clinical need and toxicity benchmarks, the more sophisticated we can be when developing the next generation of enhanced engineered cell therapies.

Theres no doubt that the challenges of delivering cell and gene therapy span the full spectrum of issues related to medicine development. However, the potential for both curative therapy and commercial opportunity is tremendous.

The scientific, clinical, technical, regulatory and commercial challenges are all surmountable when everyone in the ecosystem work together towards a shared goal, united by an unwavering focus on the patient.

Sophie and Aisha are speaking about the translational journey from science to bedside at the BioBeat19 summit.

The BioBeat19 summit on Accelerating cell and gene therapy, 1-6pm, Tuesday 19 November, GSK Stevenage. Guarantee your place by registering at http://www.biobeat19.org

Read more:

Next generation cell and gene therapies: fine tuning the promise - Business Weekly

Vertex invests in gene therapy manufacturing – BioPharma-Reporter.com

Across 2019, Vertex has struck deals intended to yield a new generation of breakthrough medicines.

In June, Vertex agreed to pay $245m (220m) upfront to acquire Exonics Therapeutics for its gene editing technology and pipeline of programs targeting diseases including Duchenne muscular dystrophy (DMD). Months later, Vertex put up another $950m to buy Semma Therapeutics and its cell therapy treatment for type I diabetes.

The acquisitions moved Vertex, which started out in small molecules, into new areas, and building out capabilities in those areas will cost money.

In recent years, Vertex has grown its annual operating expenses by 10% to 14%. Talking on a recent quarterly results conference call, Vertex CFO Charles Wagner warned investors to expect costs to rise faster in 2020.

Wagner said, Our current expectation is that the rate of growth will be somewhat higher in 2020 as we invest in research and preclinical manufacturing for selling genetic therapies in support of our programs in type I diabetes, DMD and other diseases.

The move into type I diabetes also takes Vertex into territory that, to some observers, looks different than the areas the company has targeted historically.

Asked by an analyst about the shift in focus, Vertex CEO Jeff Leiden downplayed the differences, noting that type I diabetes is treated in the US in a relatively small number ofcenters that can be targeted by a speciality sales force.

Researchers have achieved positive, long-term outcomes by transplanting cadaveric islets into patients but two barriers have stopped companies from industrialising that approach.

Firstly, there are too few cadaveric islets to treat all type I diabetics. Secondly, immunosuppression is needed to stop patients from rejecting the transplanted cells.

Semma is trying to tackle the problems by differentiating stem cells and using a device to protect them from the immune system. Vertex thinks these technologies are the breakthroughs the field needs to industrialize the concept.

Leiden said, We were watching companies who are addressing those two problems for the last two, three years. And over the last six to eight months, we were convinced that Semma has actually solved both of those problems.

Vertex reached that conclusion on the strength of preclinical data. Now, Vertex is set to invest to find out whether the idea works in the clinic.

Original post:

Vertex invests in gene therapy manufacturing - BioPharma-Reporter.com

Scientists are using gene therapy to treat a heart disease in dogs. Could humans be next? – 10News

Scientists are working to eliminate a type of heart disease in dogs using gene therapy.

They're zoning in on a heart condition called mitral valve disease thats common in 6% of dogs.

Scientists are using Cavalier King Charles spaniels for the research.

They tend to develop it at a younger age.

Scientists at Tufts University have already tested gene therapy in mice.

A virus is injected into them to deliver DNA to cells which causes them to create a protein.

What it essentially does is stops the heart valve from getting thicker, stopping the valve from leaking.

Researchers are now moving on to testing this in dogs.

But they think the treatment could go beyond just canines.

Many of the dog diseases are naturally occurring and really great models for human disease, says Dr. Vicky Yang, a veterinary cardiologist and research assistant professor at Cummings School of Veterinary Medicine at Tufts University. And I can see this, if it becomes successful in dogs, potentially going into thinking about treatment for humans for mitral valve disease.

The biotech company behind the treatment agrees. It says it could also expand beyond heart problems.

I think a larger question, though, is if we are able to prove this thesis of treating aging, making the animal generally healthier, could also treat heart failure, what other diseases could we treat in dogs? says Daniel Oliver, the CEO of Rejuvenate Bio. And could we progress this treatment onto past dogs and other animals and possibly humans?

The gene therapy would only be used for dogs just starting to experience heart problems.

Researchers still need to make sure the gene therapy is safe for all breeds before they make it available to the public.

See the article here:

Scientists are using gene therapy to treat a heart disease in dogs. Could humans be next? - 10News

Updated Alta Trial Results Support SB-525 Gene Therapy for Hemophilia A – Hemophilia News Today

Updated results from the Alta trial show that a single infusion with the highest dose of SB-525, an investigational gene therapy, yields dose-dependent and durable increases in clotting factor VIII (FVIII). The trial, in adults with severe hemophilia A , found no bleeding episodes up to 24 weeks following the infusion.

That highest dose of SB-525 31013 vector genomes, vg/kilogram, kg led patients to reach normal FVIII activity. Participants no longer needed replacement therapy following a short preventive course post-SB-525-administration.

With these promising results, Pfizer has initiated a lead-in study (NCT03587116) to support SB-525 advancement to a Phase 3 registrational clinical trial. The six-month study will evaluate the current efficacy and safety of preventive replacement therapy in the usual care setting. It is currently recruiting participants worldwide.

The Alta trials most recent findings will be shared at the upcoming 61st Annual Meeting of the American Society of Hematology (ASH), to be held Dec. 7-10 in Orlando, Fla.

Data will be featured in a poster titled Updated Follow-up of the Alta Study, a Phase 1/2, Open Label, Adaptive, Dose-Ranging Study to Assess the Safety and Tolerability of SB-525 Gene Therapy in Adult Patients with Severe Hemophilia A.

SB-525 is a gene therapy candidate to treat hemophilia A thats being developed by Sangamo Therapeutics in collaboration with Pfizer. It consists of a DNA sequence coding for the production of a working FVIII the clotting factor missing in hemophilia A. That FVIII is carried and delivered to liver cells, where clotting factors are produced, using a harmless adeno-associated viral (AAV) vector.

The goal of the therapy is for patients to regain the ability to continuously produce the coagulation factor, and reduce or eliminate the need for FVIII replacement therapy.

The therapys safety and effectiveness for the treatment of adults with severe hemophilia A are currently being evaluated in the open-label Phase 1/2 Alta trial (NCT03061201).

The study is testing a single infusion into the vein (intravenous) of one of four ascending doses of SB-525: 91011 vg/kg; 21012 vg/kg; 11013 vg/kg; and 31013 vg/kg. Two people have been dosed per group, except for the highest dose group, which was expanded to five patients.

Updated trial data now released show the results for the two patients dosed in the third group those given 11013 vg/kg and the five individuals receiving the highest dose of 31013 vg/kg.

In the third group, a single infusion of SB-525 resulted in stable and clinically relevant increases in FVIII activity.

Stronger results were seen with SB-525s highest dose. Of the five patients treated, data were available for four. For these participants, a single infusion with the highest dose of SB-525 led to normal FVIII levels with no bleeding events reported up to 24 weeks post-administration. These individuals no longer needed replacement therapy after the initial prophylactic period of up to about three weeks after SB-525 dosing.

In addition, preliminary tests from the high-dose group indicate similar activity of SB-525-derived FVIII and the clotting factor provided by Xyntha, Pfizers recombinant therapy for hemophilia A.

As to safety, one patient had treatment-related serious adverse events, namely low blood pressure and fever, occurring about six hours after infusion. These effects resolved with treatment within 24 hours, with no loss of FVIII expression.

Some patients also showed elevated blood levels of liver enzymes(ALT, alanine aminotransferase). However, these were reported to be mild and temporary increases, which were treated in a timely manner with corticosteroids.

Dosing in the fourth group is ongoing. At the upcoming meeting, Sangamo will disclose additional analyses of the trial data, including a follow-up of approximately 4 to 11 months after treatment.

The rapid kinetics of Factor VIII expression, durability of response, and the relatively low intra-cohort variability in the context of a complete cessation of bleeding events and elimination of exogenous Factor VIII usage continues to suggest SB-525 is a differentiated hemophilia A gene therapy, Bettina Cockroft, MD, MBA, chief medical officer of Sangamo said in a press release.

We are pleased with the progress of the program toward a registrational Phase 3 study led by Pfizer, who announced it has enrolled its first patient in the 6-month Phase 3 lead-in study. We have recently completed the manufacturing technology transfer to Pfizer and initiated the transfer of the IND [investigational new drug].

Ana is a molecular biologist enthusiastic about innovation and communication. In her role as a science writer she wishes to bring the advances in medical science and technology closer to the public, particularly to those most in need of them. Ana holds a PhD in Biomedical Sciences from the University of Lisbon, Portugal, where she focused her research on molecular biology, epigenetics and infectious diseases.

Total Posts: 121

Margarida graduated with a BS in Health Sciences from the University of Lisbon and a MSc in Biotechnology from Instituto Superior Tcnico (IST-UL). She worked as a molecular biologist research associate at a Cambridge UK-based biotech company that discovers and develops therapeutic, fully human monoclonal antibodies.

View original post here:

Updated Alta Trial Results Support SB-525 Gene Therapy for Hemophilia A - Hemophilia News Today